WO2004024893A2 - Nell-1 enhanced bone mineralization - Google Patents
Nell-1 enhanced bone mineralization Download PDFInfo
- Publication number
- WO2004024893A2 WO2004024893A2 PCT/US2003/029281 US0329281W WO2004024893A2 WO 2004024893 A2 WO2004024893 A2 WO 2004024893A2 US 0329281 W US0329281 W US 0329281W WO 2004024893 A2 WO2004024893 A2 WO 2004024893A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nell
- expression
- activity
- cell
- bone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Definitions
- This invention relates to the discovery that upregulation of NELL-1 enhances bone calcification.
- NELL-1 thus provides a good target to screen for modulators of bone calcification.
- NELL-1 proteins can be used in a manner analogous to bone morphogenic proteins to facilitate bone repair.
- Premature suture closure in human CS can be divided into two possibly distinct processes: calvarial overgrowth and bony fusion. While calvarial overgrowth may be essential to bringing the two opposing osteogenic fronts into proximity in order to induce bony fusion, it does not necessarily follow that calvarial overgrowth or overlap alone will result in bony fusion. Thus, the study of premature suture closure mechanisms must include study of both abnormal suture overgrowth/overlap and bony fusion (6).
- NELL-1 which is a Nel-like, type 1 molecule (a protein strongly expressed in neural tissue, encoding an EGF-like domain) (10-12).
- Nell-1 is a secreted protein.
- Nell-1 encodes a secretory signal peptide sequence, an NH2-terminal thrombospondin-1-like module, five von Willebrand factor -like repeats with six cysteine residues, and six EGFlike 306T-000300PC domains.
- Nell-1 is also highly conserved across species. For example, 93% amino acid sequence homology exists between rat Nell-1 and human NELL-1.
- Nell-1 encodes a polypeptide with a molecular weight of 90 kDa.
- the glycosylated form is N-linked to a 50-kDa carbohydrate moiety in eukaryotic cells to generate the 140-kDa form found in the cytoplasm.
- This 140- kDa protein is further processed to a 130-kDa protein.
- the Nell-1 protein is secreted as a trimeric form with a high molecular weight (approximately 400 kDa) (13, 14).
- Nell-1 is preferentially expressed in the craniofacial region of calvarial tissues (12-14). Premature suture closure in CS patients is remarkable for the degree of NELL-1 overexpression by osteoblast-like cells in osteogenic areas (12). Although Nell-1 overexpression and premature suture closure may be coincidental findings, our data suggest that Nell-1 may be a local regulatory factor in cranial suture closure. In this study, we further verified that Nell-1 has a role in CS. We created a transgenic mouse model exhibiting generalized Nell-1 overexpression. Nell-1 transgenic animals share many of the same features as humans with CS. They demonstrate calvarial overgrowth/overlap and premature suture closure.
- Nell-1 represents a candidate gene for producing cranial suture closure and provides new insights in the study of CS and craniofacial development.
- this invention provides methods of modulating calvarial osteoblast differentiation and mineralization.
- the methods involve altering expression or activity of Nell-1, where increased expression or activity of Nell-1 increases osteoblast differentiation or mineralization and decreased expression or activity of Nell-decreases osteoblast differentiation or mineralization.
- Nell-1 expression or activity is can be inhibited by any convenient method (e.g. an anti-Nell-1 antisense molecule, a Nell-1 specific ribozyme, a Nell-1 specific catalytic DNA, a Nell-1 specific RNAi, anti-Nell-1 intrabodies, and gene therapy approaches that knock out Nell-1 in particular target cells and/or tissues).
- Nell-1 expression or activity can be increased by any convenient method (e.g.
- the mammal can be a mammal (human or non-human mammal) experiencing abnormal cranial suture development (e.g. Craniosynostosis (CS)).
- CS Craniosynostosis
- This invention also provides a method of facilitating latent TGF- ⁇ l activation in a mammal.
- the method can involve administering exogenous Nell-1 to the mammal, or increasing expression activity of endogenous Nell-1 in said mammal.
- [0013] Also provides is a method of activating or sequestering a member of the TGF- ⁇ superfamily in a mammal.
- the method involves administering exogenous Nell-1 to teh mammal, or increasing expression activity of endogenous Nell-1 in the mammal.
- this invention provides methods of screening for an agent that modulates osteoblast differentiation.
- the methods involve contacting a test cell containing a NELL-1 gene with a test agent; and detecting a change in the expression level of a NELL-1 gene or the activity of Nell-1 in the test cell as compared to the expression of the NELL-1 gene or the activity of Nell-1 in a control cell where a difference in the expression level of NELL-1 or the activity of Nell-1 in the test cell and the control cell indicates that said agent modulates bone mineralization.
- the control is a negative control cell contacted with the test agent at a lower concentration (e.g. half concentration, absense of test agent, etc.) than the test cell.
- control is a positive control cell contacted with the test agent at a higher concentration than the test cell.
- expression level of nell-1 is detected by measuring the level of NELL-1 mRNA in said cell and/or the level of NELL-1 is detected by determining the expression level of a NELL-1 protein in the biological cell, e.g. as described herein.
- this invention provides methods of altering Nell-
- Msx2 and/or Cbfal are altered to upregulate Nell-1 expression or activity.
- Msx2 expression or activity is upregulated to downregulate Nell-1 expression or activity.
- Nell-1 expression or activity said method comprising where the methods involve contacting a test cell containing a Cbfal and/or an Msx2 gene with a test agent; and detecting a change in the expression level of an Cbfal and/or an Msx2gene or the activity of Cbfal and/or an Msx2 in said test cell as compared to the expression of the Cbfal and/or an Msx2 gene or the activity of Cbfal and/or an Msx2 in a control cell where a difference in the expression level 306T-000300PC of Cbfal and/or an Msx2or the activity of Cbfal and/or an Msx2 in the test cell and the control cell indicates that the agent modulates Nell-1 expression or activity.
- a pharmaceutical formulation comprising : one or more active agents selected from the group consisting of a nucleic acid encoding a Nell-1 protein, a Nell-1 protein, and an agent that alters expression or activity of a Nell-1 protein; and a pharmaceutically acceptable excipient.
- this invention pertains to the discovery that the polypeptide encoded by the human NELL-1 gene induces bone mineralization and is therefore osteogenic.
- the NELL-1 gene and gene product(s) e.g. ITJRNA, cDNA, protein, etc.
- NELL-1 can be used in a manner analogous to the use of bone morphogenic proteins (BMPs) to speed fracture repair and as a component of bone graft materials.
- BMPs bone morphogenic proteins
- this invention provides methods of screening for an agent that alters bone mineralization.
- the methods involve contacting a cell containing a NELL-1 gene with a test agent; and detecting a change in the expression level of the NELL-1 gene as compared to the expression of the NELL-1 gene in a cell that is not contacted with the test agent where a difference in the expression level (e.g. as represented by genomic DNA copy number, mRNA level, protein level, protein activity, etc.), of NELL-1 in the contacted cell and the cell that is not contacted indicates that said agent modulates bone mineralization.
- a difference in the expression level e.g. as represented by genomic DNA copy number, mRNA level, protein level, protein activity, etc.
- the methods may further involve test agents that alter expression of the NELL-1 nucleic acid or the NELL-1 protein in a database of modulators of NELL-1 activity or in a database of modulators of bone mineralization.
- the expression level of NELL-1 is detected by measuring the level of NELL-1 mRNA in the cell (e.g. by hybridizing said mRNA to a probe that specifically hybridizes to a NELL-1 nucleic acid).
- Preferred hybridization methods include, but are not limited to a Northern blot, a Southern blot using DNA derived from the NELL-1 RNA, an array hybridization, an affinity chromatography, and an in situ hybridization. The methods of this invention are amenable to array-based approaches.
- the probe is a member of a plurality of probes that forms an array of probes.
- the level of NELL-1 expression can also be determined using a nucleic acid amplification reaction (e.g. PCR). 306T-000300PC
- NELL-1 expression is detected by determining the expression level of a NELL-1 protein (e.g. via of capillary electrophoresis, a Western blot, mass spectroscopy, ELISA, immunochromatography, immunohistochemistry, etc.) in the biological sample.
- the cell can be cultured ex vivo or can be in vivo and/or in situ.
- the test agent is not an antibody and/or not a protein and or not a nucleic acid.
- Preferred test agents are small organic molecules.
- This invention also provides methods of prescreening for a potential modulator of NELL-1 expression and/or activity.
- the methods involve contacting a NELL-1 nucleic acid or a NELL-1 protein with a test agent; and detecting specific binding of said test agent to the NELL-1 protein or nucleic acid.
- the method can further involve recording test agents that specifically bind to the NELL-1 nucleic acid or to said NELL-1 protein in a database of candidate modulators of NELL-1 activity and/or in a database of candidate modulators of bone mineralization.
- the test agent can be contacted directly to the NELL-1 nucleic acid and/or protein, or to a cell and/or tissue and/or organism (e.g., mammal) containing the nucleic acid and/or protein.
- the cell can be in a primary or passaged culture.
- the test agent is not an antibody and/or not a protein and/or not a nucleic acid.
- Preferred test agents are small organic molecules.
- the assay measures the ability of the test agent to bind to a nucleic acid preferred assays utilize a Northern blot, a Southern blot using DNA, an array hybridization, an affinity chromatography, or an in situ hybridization.
- preferred assays utilize capillary electrophoresis, a Western blot, mass spectroscopy, ELISA, immunochromatography, or immunohistochemistry).
- this invention provides methods of increasing bone mineralization.
- Preferred methods involve increasing the concentration of a NELL-1 gene product in an osteogenic cell (e.g. an osteoblast, a mesenchymal cell, a fibroblast cell, a fetal embryonic cell, a stem cell, a bone marrow cell, a dura cell, a chrondrocyte, a chondroblast, etc.) or in the milieu within which the cell is found.
- the concentration of NELL-1 gene product is increased by upregulating expression of a NELL-1 gene. This can be accomplished by any of a wide variety of methods including, but not limited to upregulating expression of an endogenous NELL-1 gene (e.g.
- the NELL-1 gene product concentration is increased by the bone with a NELL-1 polypeptide.
- This invention also provides methods of facilitating the repair of bone fractures. These methods involve increasing concentration of a NELL-1 gene product at or near the fracture site. In preferred embodiments, the NELL-1 gene product is increased in an osteogenic or bone precursor cell present at or near the fracture site.
- the methods can involve introducing an osteogenic cell or bone precursor cell that overexpresses NELL-1 into the fracture site.
- this invention can involve increasing the concentration of a NELL-1 gene product in the osteogenic cell or said bone precursor cell in situ.
- the NELL-1 gene product up-regulation can be achieved as described herein.
- the cell andor bone fracture site is contacted with a NELL-1 polypeptide.
- the fracture site is contacted with a NELL-1 polypeptide.
- the protein can be produced by a cell (e.g. introduced by introduction of a cell overexpressing NELL-1 protein) and/or by administration of the protein alone or in combination with a pharmacological excipient, and/or by administration of a "naked DNA" vector capable of expressing NELL-1.
- the NELL-1 protein can be a component of a bone repair/bone graft material and/or part of a prosthetic device.
- One preferred graft material includes collagen and/or bone fragments in addition to the NELL-1 protein and/or cells expressing a NELL-1 protein.
- this invention provides a bone graft material capable of enhancing the formation of osseous tissue in the animal in which it is implanted.
- Preferred bone graft materials consist essentially of a biocompatible matrix and a NELL-1 protein.
- a preferred graft material is resorbable/biodegradeable.
- the matrix can be impregnated with a NELL-1 protein and/or a cell expressing a NELL-1 protein.
- a preferred bone graft material comprises a collagen conjugate containing: (e.g., about 65 to about 95 weight percent) reconstituted collagen having dispersed substantially uniformly therein; and (e.g. , about 35 to about 5 weight percent) a NELL-1 protein and/or a cell expressing a NELL-1 protein.
- polypeptide peptide
- protein protein
- amino acid polymers in which one or more amino acid residue is an artificial chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers.
- NELL-1 cDNA and “NELL-1" genomic DNA refer to the cDNA and genomic DNA as disclosed by Watanabe et al. (1996) Genomics 38 (3): 273-276; Ting et al. (1999) J Bone Mineral Res, 14: 80-89; and GenBank Accession Number U57523).
- a NELL-1 protein is a protein expressed by the NELL-1 gene or cDNA.
- NELL-1 protein can include NELL-1 protein fragments that retain the ability to induce bone mineralization.
- antibody includes various forms of modified or altered antibodies, such as an intact immunoglobulin, an Fv fragment containing only the light and heavy chain variable regions, an Fv fragment linked by a disulfide bond
- the antibody may be of animal (especially mouse or rat) or human origin or may be chimeric (Morrison et al. (1984) Proc Nat. Acad. Sci. USA 81: 6851-6855) or humanized (Jones et al. (1986) Nature 321: 522-525, and published UK patent application #8707252).
- binding partner or “capture agent”, or a member of a “binding pair” refers to molecules that specifically bind other molecules to form a binding complex such as antibody-antigen, lectin-carbohydrate, nucleic acid-nucleic acid, biotin-avidin, etc.
- the 306T-000300PC specified ligand or antibody binds to its particular "target" molecule and does not bind in a significant amount to other molecules present in the sample.
- osteoporosis refers to a heterogeneous group of disorders characterized by decreased bone mass and fractures. Clinically, osteoporosis is segregated into type I and type II. Type I osteoporosis occurs predominantly in middle aged women and is associated with estrogen loss at the menopause, while osteoporosis type II is associated with advancing age.
- Osteogenesis imperfecta refers to a group of inherited connective tissue diseases characterized by bone and soft connective tissue fragility (Byers & Steiner (1992) Annu. Rev. Med. 43: 269-289; Prockop (1990) J. Biol. Chem. 265: 15349-15352). Males and females are affected equally, and the overall incidence is currently estimated to be 1 in 5,000-14,000 live births. Hearing loss, dentinogenesis imperfecta, respiratory insufficiency, severe scoliosis and emphysema are just some of the conditions that are associated with one or more types of OI. While accurate estimates of the health care costs are not available, the morbidity and mortality associated with OI certainly result from the extreme propensity to fracture (OI types I-IN) and the deformation of abnormal bone following fracture repair (OI types II-IN).
- nucleic acid or “oligonucleotide” or grammatical equivalents herein refer to at least two nucleotides covalently linked together.
- a nucleic acid of the present invention is preferably single-stranded or double stranded and will generally contain phosphodiester bonds, although in some cases, as outlined below, nucleic acid analogs are included that may have alternate backbones, comprising, for example, phosphoramide (Beaucage et al. (1993) Tetrahedron 49(10): 1925) and references therein; Letsinger (1970) J. Org. Chem. 35:3800; Sblul et al. (1977) Eur. J. Biochem. 81: 579; Letsinger et al. (1986) Nucl. Acids Res. 14: 3487; Sawai et al. (1984) Chem. Lett. 805, Letsinger et al.
- nucleic acids include those with positive backbones (Denpcy et al. (1995)
- nucleic acids containing one or more carbocyclic sugars are also included within the definition of nucleic acids (see Jenkins et al. (1995), Chem. Soc. Rev. ppl69-176).
- nucleic acid analogs are described in Rawls, C & E News June 2, 1997 page 35. These modifications of the ribose-phosphate backbone may be done to facilitate the addition of additional moieties such as labels, or to increase the stability and half-life of such molecules in physiological environments.
- “selectively hybridize to,” as used herein refer to the binding, duplexing, or hybridizing of a nucleic acid molecule preferentially to a particular nucleotide sequence under stringent conditions.
- stringent conditions refers to conditions under which a probe will hybridize preferentially to its target subsequence, and to a lesser extent to, or not at all to, other sequences.
- Stringent hybridization and stringent hybridization wash conditions in the context of nucleic acid hybridization are sequence dependent, and are different under different environmental parameters. An extensive guide to the hybridization of nucleic acids is found in, e.g., Tijssen (1993) Laboratory Techniques in Biochemistry and Molecular
- a high stringency wash is preceded by a low stringency wash to remove background probe signal.
- An example of a low stringency wash for a duplex of, e.g., more than 100 nucleotides, is 4x to 6x SSC at 40°C for 15 minutes.
- Osteogenic cells are cells capable of mineralizing. Osteogenic cells include osteoblasts, osteoblast like cells, mesenchymal cells, fibroblast cells, fetal embryonic cells, stem cells, bone marrow cells, dura cells, chrondrocyes, and chondroblastic cells.
- test agent refers to an agent that is to be screened in one or more of the assays described herein.
- the agent can be virtually any chemical compound. It can exist as a single isolated compound or can be a member of a chemical (e.g. combinatorial) library. In a particularly preferred embodiment, the test agent will be a small organic molecule.
- small organic molecule refers to a molecule of a size comparable to those organic molecules generally used in pharmaceuticals.
- Preferred small organic molecules range in size up to about 5000 Da, more preferably up to 2000 Da, and most preferably up to about 1000 Da.
- the term database refers to a means for recording and retrieving information.
- the database also provides means for sorting and/or searching the stored information.
- the database can comprise any convenient media including, but not limited to, paper systems, card systems, mechanical systems, electronic systems, optical systems, magnetic systems or combinations thereof.
- Preferred databases include electronic (e.g. computer-based) databases.
- Computer systems for use in storage and manipulation of 306T-000300PC databases are well known to those of skill in the art and include, but are not limited to
- personal computer systems mainframe systems, distributed nodes on an inter- or intra-net, data or databases stored in specialized hardware (e.g. in microchips), and the like.
- Figure 1 A illustrates over-expression of NELL-1 in E-14 rat calvarial primary cell cultures using adenoviruses with ⁇ -galactosidase as control.
- Figure IB shows a plot of mineralization as a function of time post treatment with NELL-1 and ⁇ -glactosidase respectively. Experiments were performed in triplicate. Student's T test was performed. Mineralization with NELL-l was statistically higher than mineralization with ⁇ -Galactosidase control, *P ⁇ 0.001.
- Figure 2 illustrates Nell-1 transgenic mice compared with nontransgenic littermates.
- Figure 2A Transgene copy number.
- the founders (FA and FB) and their progeny (TF 2 A1, TF A2, and TF 2 B1) have copy numbers between 50 and 100.
- TF 2 A1 and TF 2 A2 are from the founder A line.
- TF 2 B1, TF 2 B2, and TF 2 B3 are from the founder B line.
- Figure 2B RT-PCR analyses of Nell-1 RNA expression in both founders.
- C control Nell-1 plasmid
- M muscle
- H heart
- B bone
- K kidney
- L liver.
- Figure 2C Whole body (without head) RNA of newborn progeny.
- TF2A1 and TF2A2 express different levels of Nell-1.
- TF2B1 expresses Nell-1 weakly, while TF2B2 and TF2B3 have no Nell-1 expression.
- Figure 2D Left panels, immunolocalization of Nell-1 protein in newborn NF2 epithelium, muscle, and calvarial bone. There is no detectable Nell-1 expression (brown staining indicates the presence of Nell-1) except some staining in the calvarial bone.
- Right panels immunolocalization of Nell-1 protein in TF2A2 epithelium, muscle, and calvarial bone. Abundant Nell-1 expression is present throughout all soft tissue layers as well as in bone. Bar represents 50 ⁇ m.
- FIG. 3 Phenotypic evaluation of Nell-1 transgenic mice, (a and b) Left panels show a newborn Nell-1 phenotype-positive (TF2A1) mouse. Note the protrusion in the frontoparietal area (arrows). Right panels show an NF2 littermate. (c) Left panel, TF2A2 mouse with the scalp removed. The sagittal (yellow arrow) and PF (black arrow) sutures are closed. Right panel, skull of the NF2 littermate with patent sagittal (yellow arrows) and PF (black arrow) sutures and normal vasculature underneath the patent sutures, (d) An infant with craniotelencephalic dysplasia, a severe form of CS. (e) Brain MRI of TF 2 A1 mouse 306T-000300PC
- Green arrows indicate increased mineralization of the calvarium in the TF2A mouse (arrow, right).
- FIG. 4 Histologic and immunohistologic evaluation of Nell-1 transgenic mice.
- (Panel a) Hematoxylin and eosin staining of the sagittal suture of a Nell-1 phenotype- positive TF2A1 mouse. There is closure of the suture, shown by the overlap of calvarial edges (black arrows) and closing osteogenic fronts (red arrows). Lower left panel shows von Kossa staining. Note the close proximity of mineralized calvarial edges.
- Panel b Hematoxylin and eosin staining of the sagittal suture from an NF2 littermate.
- FIG. 5 Nell-1 transgenic TF 2 B1 mouse compared with a nontransgenic littermate.
- (a) Left, newborn TF2B1 mouse with the scalp removed. Note the abnormal bulging of the occipital area and the relatively narrow width of the cranium. Right, an NF2 littermate.
- the sagittal suture and several other sutures are closed
- (b) Hematoxylin and eosin staining of TF2B1 sagittal suture Premature closure of the suture is manifest in the severe overlap of calvarial edges (red arrows).
- FIG. 6 illustrates the effects of Nell-1 overexpression on mineralization and bone marker expression.
- Figure 6 A FRCC culture infected with 20 pfu/cell AdNell-1, stained with von Kossa stain. Control cell cultures were infected with Ad ⁇ -Gal. Experiments were performed in triplicate. Mineralized nodules are stained black.
- Figure 6B Quantitation and statistical analysis of mineralized areas.
- AdNeZZ-i-infected cultures demonstrated significantly greater mineralization than did Ad -Gal controls.
- Figure 6C AdNeW-i-infected MC3T3 cells grown without ascorbic acid. Typical micronodule appearance is shown. Right panel represents alkaline phosphatase staining of a micronodule.
- Figures 6D-F Microarrays of AcLNeZZ-infected MC3T3 cells on postinfection days 6, 9, and 12, respectively. Gene expression intensities have been normalized using standardized housekeeping genes (HKGs). Hybridization intensities of AdNeZZ-i-infected cells are represented on the y axis.
- Hybridization intensities of Ad ⁇ -G Z-infected cells are represented on the x axis.
- HKGs r2 represents the correlation of housekeeping genes (filled squares) between the two samples.
- ECMs r2 represents the correlation of candidate gene expression (open squares) between the two samples.
- a photograph of the microarray reading is attached in the upper left corner of each diagram.
- a twofold or greater upregulation is represented in red, while a twofold or greater downregulation is represented in green (g)
- Figure 7 illustrates the effect of ⁇ ell-1 downregulation on alkaline phosphatase expression and bone marker expression.
- Figure 7A Western blot analysis of ⁇ ell-1 protein expression in rat FRCCs infected with 20 pfu/cell AdAntiNeZZ-i or Ad ⁇ -G ⁇ Z control. Downregulation of approximately 60% is observed.
- Figure 7B Alkaline 306T-000300PC phosphatase staining (in red) of FRCCs. AdAntiNeZZ-.. -infected cells have significantly less staining than do control and AdNeZZ-i-infected cells.
- Figure 7C Northern analyses of
- Figure 8 illustrates a hypothetical model of Nell-1 function in premature suture closure. Dashed line represents potential modulation.
- This invention provides pertains to the discovery that the NELL-1 gene product enhances tissue (e.g. bone) mineralization. Without being bound to a particular theory, it is believed that the NELL-1 protein may execute its function by interacting with members of the TGF ⁇ superfamily.
- NELL-1 nucleic acids and/or NELL-1 proteins provide convenient targets for screening for modulators of bone mineralization.
- agents that inhibit NELL-1 expression and/or protein activity and/or protein-protein interactions will decrease bone mineralization.
- agents that upregulate NELL-1 expression and/or protein activity and/or protein-protein interactions are expected to increase bone mineralization.
- Such NELL-1 "agonists" are expected to be useful in a wide variety of contexts including, but not limited treatment of osteoporosis, bone fracture healing, treatment of osteogenesis imperfecta, bone reconstruction, and the like.
- this invention provides methods of identifying agents that modulate (e.g. up-regulate or down-regulate) NELL-1 expression. Such methods involve contacting a NELL-1 nucleic acid , and/or a cell containing a NEL1-1 nucleic acid, and/or a tissue or organism comprising cells containing a NELL-1 nucleic acid and detecting changes in the level of NELL-1 transcript (e.g. mRNA) and/or NELL-1 protein.
- candidate test agents for such an assay are identified in a binding assay "pre- screen”.
- Such a binding assay involves pre-screening test agent(s) for the ability to specifically bind to a NELL-1 nucleic acid and/or a NELL-1 protein. Agents identified by theses assays that upregulate NELL-1 expression are expected to be useful in the treatment of osteoporosis and bone fractures. 306T-000300PC
- the NELL-1 polypeptide(s) can be used to speed repair of bone fractures or to induce bone repair or replacement under circumstances where natural healing is limited or non-existent.
- methods involve increasing the amount of a NELL-1 gene product at or near the fracture site in a bone.
- the NELL-1 gene product concentration can be increased by one or more of a number of methods.
- cells at or near the bone fracture site are induced to express elevated levels of NELL-1. This is accomplished, for example, by the use of modulators of NELL-1 expression, by altering the NELL-1 promoter, or by transfecting the cell with a construct that expresses NELL-1. This can be accomplished in vivo, or, in another embodiment, such cells can be modified to overexpress NELL-1 ex vivo and then introduced back into the subject organism (e.g. at or near a fracture site).
- Cells expressing or overexpressing NELL-1 can be incorporated into bone graft materials and/or NELL-1 polypeptides can be incorporated into such bone graft materials. These graft materials can be used in the treatment of fractures or to facilitate the replacement healing of prostheses or bone transplants.
- this invention is premised on the discovery that NELL-1 mediates mineralization of bone and thus provides a good target for new agents that modulate bone mineralization.
- this invention provides methods of screening for agents that modulate NELL-1 expression and hence bone mineralization. The methods involve detecting the expression level and/or activity level of a NELL-1 gene or gene product (e.g. NELL-1 protein) in the presence of the agent(s) in question. An elevated NELL-1 expression level or activity level in the presence of the agent as compared to a negative control where the test agent is absent or at reduced concentration indicates that the agent upregulates NELL-1 activity or expression.
- a NELL-1 gene or gene product e.g. NELL-1 protein
- NELL-1 expression level or activity level in the presence of the agent as compared to a negative control where the test agent is absent or at reduced concentration indicates that the agent down-regulates NELL-1 activity or expression
- Expression levels of a gene can be altered by changes in by changes in the transcription of the gene product (i.e. transcription of mRNA), and/or by changes in 306T-000300PC translation of the gene product (i.e. translation of the protein), and/or by post-translational modification(s) (e.g. protein folding, glycosylation, etc.).
- preferred assays of this invention include assaying for level of transcribed mRNA (or other nucleic acids derived from the NELL-1 gene), level of translated protein, activity of translated protein, etc. Examples of such approaches are described below.
- Changes in expression level can be detected by measuring changes in mRNA and or a nucleic acid derived from the mRNA (e.g. reverse-transcribed cDNA, etc.).
- a nucleic acid sample for such analysis.
- the nucleic acid is found in or derived from a biological sample.
- biological sample refers to a sample obtained from an organism or from components (e.g., cells) of an organism. The sample may be of any biological tissue or fluid. Biological samples may also include organs or sections of tissues such as frozen sections taken for histological purposes.
- the nucleic acid (e.g., mRNA nucleic acid derived from mRNA) is, in certain preferred embodiments, isolated from the sample according to any of a number of methods well known to those of skill in the art. Methods of isolating mRNA are well known to those of skill in the art. For example, methods of isolation and purification of nucleic acids are described in detail in by Tijssen ed., (1993) Chapter 3 of Laboratory Techniques in Biochemistry and Molecular Biology: Hybridization With Nucleic Acid Probes, Part I. Theory and Nucleic Acid Preparation, Elsevier, N.Y. and Tijssen ed.
- the "total" nucleic acid is isolated from a given sample using, for example, an acid guanidinium-phenol-chloroform extraction method and polyA+ mRNA is isolated by oligo dT column chromatography or by using (dT)n magnetic beads (see, e.g., Sambrook et al, Molecular Cloning: A Laboratory Manual (2nd ed.), Nols. 1-3, Cold Spring Harbor Laboratory, (1989), or Current Protocols in Molecular Biology, F. Ausubel et al, ed. Greene Publishing and Wiley-Interscience, New York (1987)).
- PCR polymerase chain reaction
- LCR ligase chain reaction
- the nucleic acid sample is one in which the concentration of the NELL-1 mRNA transcript(s), or the concentration of the nucleic acids derived from the NELL-1 mRNA transcript(s), is proportional to the transcription level (and therefore expression level) of that gene.
- the hybridization signal intensity be proportional to the amount of hybridized nucleic acid.
- the proportionality be relatively strict (e.g., a doubling in transcription rate results in a doubling in mRNA transcript in the sample nucleic acid pool and a doubling in hybridization signal), one of skill will appreciate that the proportionality can be more relaxed and even non-linear. Thus, for example, an assay where a 5 fold difference in concentration of the target mRNA results in a 3 to 6 fold difference in hybridization intensity is sufficient for most purposes. [0060] Where more precise quantification is required appropriate controls can be run to correct for variations introduced in sample preparation and hybridization as described herein.
- serial dilutions of "standard" target nucleic acids can be used to prepare calibration curves according to methods well known to those of skill in the art.
- standard target nucleic acids e.g., mRNAs
- the NELL-1 -containing nucleic acid sample is the total mRNA or a total cDNA isolated and/or otherwise derived from a biological sample.
- the nucleic acid may be isolated from the sample according to any of a number of methods well known to those of skill in the art as indicated above. 306T-000300PC
- NELL-1 reverse-transcribed cDNA involves a "Southern Blot".
- DNA e.g., reverse-transcribed N ⁇ LL-1 mRNA
- control e.g. a probe for a "housekeeping gene
- the NELL-1 mRNA can be directly quantified in a Northern blot.
- the mRNA is isolated from a given cell sample using, for example, an acid guanidinium-phenol-chloroform extraction method. The mRNA is then electrophoresed to separate the mRNA species and the mRNA is transferred from the gel to a nitrocellulose membrane.
- labeled probes are used to identify and/or quantify the target NELL-1 mRNA.
- Appropriate controls e.g. probes to housekeeping genes provide a reference for evaluating relative expression level.
- in situ hybridization An alternative means for determining the NELL-1 expression level is in situ hybridization.
- In situ hybridization assays are well known (e.g., Angerer (1987) Meth. Enzymol 152: 649).
- in situ hybridization comprises the following major steps: (1) fixation of tissue or biological structure to be analyzed; (2) prehybridization treatment of the biological structure to increase accessibility of target DNA, and to reduce nonspecific binding; (3) hybridization of the mixture of nucleic acids to the nucleic acid in the biological structure or tissue; (4) post-hybridization washes to remove nucleic acid fragments not bound in the hybridization and (5) detection of the hybridized nucleic acid fragments.
- the reagent used in each of these steps and the conditions for use vary depending on the particular application.
- tRNA human genomic DNA
- Cot-1 DNA is used to block non-specific hybridization.
- amplification-based assays can be used to measure
- NELL-1 expression (transcription) level In such amplification-based assays, the target nucleic acid sequences (i.e., NELL-1 ) act as template(s) in amplification reaction(s) (e.g. Polymerase Chain Reaction (PCR) or reverse-transcription PCR (RT-PCR)). In a quantitative amplification, the amount of amplification product will be proportional to the amount of template (e.g., NELL-1 mRNA) in the original sample. Comparison to appropriate (e.g. healthy tissue or cells unexposed to the test agent) controls provides a measure of the NELL-1 transcript level. [0067] Methods of "quantitative" amplification are well known to those of skill in the art.
- quantitative PCR involves simultaneously co-amplifying a known quantity of a control sequence using the same primers. This provides an internal standard that may be used to calibrate the PCR reaction.
- Detailed protocols for quantitative PCR are provided in Innis et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, Inc. N.Y.).
- One approach for example, involves simultaneously co-amplifying a known quantity of a control sequence using the same primers as those used to amplify the target. This provides an internal standard that may be used to calibrate the PCR reaction.
- One preferred internal standard is a synthetic AW106 cRNA.
- the AW106 cRNA is combined with RNA isolated from the sample according to standard techniques known to those of skill in the art.
- the RNA is then reverse transcribed using a reverse transcriptase to provide copy DNA.
- the cDNA sequences are then amplified (e.g., by PCR) using labeled primers.
- the amplification products are separated, typically by electrophoresis, and the amount of labeled nucleic acid (proportional to the amount of amplified product) is determined.
- the amount of mRNA in the sample is then calculated by comparison with the signal produced by the known AW 106 RNA standard.
- the methods of this invention can be utilized in array- based hybridization formats.
- Arrays are a multiplicity of different "probe” or “target” nucleic acids (or other compounds) attached to one or more surfaces (e.g., solid, membrane, or gel).
- the multiplicity of nucleic acids (or other moieties) is attached to a single contiguous surface or to a multiplicity of surfaces juxtaposed to each other.
- "low density" arrays can simply be produced by spotting (e.g. by hand using a pipette) different nucleic acids at different locations on a solid support (e.g. a glass surface, a membrane, etc.).
- a solid support e.g. a glass surface, a membrane, etc.
- This simple spotting, approach has been automated to produce high density spotted arrays (see, e.g., U.S. Patent No: 5,807,522).
- This patent describes the use of an automated system that taps a microcapillary against a surface to deposit a small volume of a biological sample. The process is repeated to generate high density arrays.
- Arrays can also be produced using oligonucleotide synthesis technology.
- U.S. Patent No. 5,143,854 and PCT Patent Publication Nos. WO 90/15070 and 92/10092 teach the use of light-directed combinatorial synthesis of high density oligonucleotide arrays. Synthesis of high density arrays is also described in U.S. Patents 5,744,305, 5,800,992 and 5,445,934. 306T-000300PC b) Other hybridization formats.
- nucleic acid hybridization formats are known to those skilled in the art.
- common formats include sandwich assays and competition or displacement assays.
- assay formats are generally described in Hames and Higgins (1985) Nucleic Acid Hybridization, A Practical Approach, IRL Press; Gall and Pardue (1969) Proc. Natl. Acad. Sci. USA 63: 378-383; and John et al. (1969) Nature 223: 582-587.
- Sandwich assays are commercially useful hybridization assays for detecting or isolating nucleic acid sequences. Such assays utilize a "capture" nucleic acid covalently immobilized to a solid support and a labeled "signal" nucleic acid in solution. The sample will provide the target nucleic acid. The "capture” nucleic acid and “signal” nucleic acid probe hybridize with the target nucleic acid to form a "sandwich” hybridization complex. To be most effective, the signal nucleic acid should not hybridize with the capture nucleic acid.
- labeled signal nucleic acids are used to detect hybridization.
- Complementary nucleic acids or signal nucleic acids may be labeled by any one of several methods typically used to detect the presence of hybridized polynucleotides. The most common method of detection is the use of autoradiography with 3 H, 125 1, 35 S, 14 C, or 32 P- labelled probes or the like.
- Other labels include ligands that bind to labeled antibodies, fluorophores, chemi-luminescent agents, enzymes, and antibodies which can serve as specific binding pair members for a labeled ligand.
- Detection of a hybridization complex may require the binding of a signal generating complex to a duplex of target and probe polynucleotides or nucleic acids. Typically, such binding occurs through ligand and anti-ligand interactions as between a ligand-conjugated probe and an anti-ligand conjugated with a signal.
- the sensitivity of the hybridization assays may be enhanced through use of a nucleic acid amplification system that multiplies the target nucleic acid being detected. Examples of such systems include the polymerase chain reaction (PCR) system and the ligase chain reaction (LCR) system. Other methods recently described in the art are the nucleic acid sequence based amplification (NASB AO, Cangene, Mississauga, Ontario) and Q Beta Replicase systems. 306T-000300PC c) Optimization of hybridization conditions.
- PCR polymerase chain reaction
- LCR ligase chain reaction
- Nucleic acid hybridization simply involves providing a denatured probe and target nucleic acid under conditions where the probe and its complementary target can form stable hybrid duplexes through complementary base pairing. The nucleic acids that do not form hybrid duplexes are then washed away leaving the hybridized nucleic acids to be detected, typically through detection of an attached detectable label. It is generally recognized that nucleic acids are denatured by increasing the temperature or decreasing the salt concentration of the buffer containing the nucleic acids, or in the addition of chemical agents, or the raising of the pH. Under low stringency conditions (e.g., low temperature and/or high salt and/or high target concentration) hybrid duplexes (e.g., DNA:DNA,
- hybridization conditions may be selected to provide any degree of stringency. In a preferred embodiment, hybridization is performed at low stringency to ensure hybridization and then subsequent washes are performed at higher stringency to eliminate mismatched hybrid duplexes. Successive washes may be performed at increasingly higher stringency (e.g., down to as low as 0.25 X SSPE at 37°C to 70°C) until a desired level of hybridization specificity is obtained. Stringency can also be increased by addition of agents such as formamide. Hybridization specificity may be evaluated by comparison of hybridization to the test probes with hybridization to the various controls that can be present.
- hybridization specificity stringency
- signal intensity signal intensity
- the wash is performed at the highest stringency that produces consistent results and that provides a signal intensity greater than approximately 10% of the background intensity.
- the hybridized array may be washed at successively higher stringency solutions and read between each wash. Analysis of the data sets thus produced will reveal a wash stringency above which the hybridization pattern is not appreciably altered and which provides adequate signal for the particular probes of interest.
- background signal is reduced by the use of a blocking reagent (e.g., tRNA, sperm DNA, cot-1 DNA, etc.) during the hybridization to reduce non-specific binding.
- a blocking reagent e.g., tRNA, sperm DNA, cot-1 DNA, etc.
- the use of blocking agents in hybridization is well known to those of skill in the art (see, e.g., Chapter 8 in P. Tijssen, supra.)
- Methods of optimizing hybridization conditions are well known to those of skill in the art (see, e.g., Tijssen (1993) Laboratory Techniques in Biochemistry and Molecular Biology, Vol. 24: Hybridization With Nucleic Acid Probes, Elsevier, N. Y.).
- Optimal conditions are also a function of the sensitivity of label (e.g., fluorescence) detection for different combinations of substrate type, fluorochrome, excitation and emission bands, spot size and the like.
- label e.g., fluorescence
- Low fluorescence background surfaces can be used (see, e.g., Chu (1992) Electrophoresis 13:105-114).
- the sensitivity for detection of spots ("target elements") of various diameters on the candidate surfaces can be readily determined by, e.g., spotting a dilution series of fluorescently end labeled DNA fragments. These spots are then imaged using conventional fluorescence microscopy.
- the sensitivity, linearity, and dynamic range achievable from the various combinations of fluorochrome and solid surfaces can thus be determined.
- Serial dilutions of pairs of fluorochrome in known relative proportions can also be analyzed. This determines the accuracy with which fluorescence ratio measurements reflect actual fluorochrome ratios over the dynamic range permitted by the detectors and fluorescence of the 1 substrate upon which the probe has been fixed.
- the probes used herein for detection of NELL-1 expression levels can be full length or less than the full length of the NELL-1 mRNA. Shorter probes are empirically tested for specificity. Preferred probes are sufficiently long so as to specifically hybridize with the NELL-1 target nucleic acid(s) under stringent conditions.
- the preferred size range is from about 20 bases to the length of the NELL-1 mRNA, , more preferably from about 30 bases to the length of the NELL-1 mRNA, and most preferably from about 40 bases to the length of the NELL-1 mRNA.
- the probes are typically labeled, with a detectable label.
- Detectable labels suitable for use in the present invention include any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means.
- Useful 306T-000300PC labels in the present invention include biotin for staining with labeled streptavidin conjugate, magnetic beads (e.g., DynabeadsTM), fluorescent dyes (e.g., fluorescein, texas red, rhodamine, green fluorescent protein, and the like, see, e.g., Molecular Probes, Eugene,
- radiolabels e.g., 3 H, 125 1, 35 S, 14 C, or 32 P
- enzymes e.g., horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA
- colorimetric labels such as colloidal gold (e.g., gold particles in the 40 -80 nm diameter size range scatter green light with high efficiency) or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads.
- Patents teaching the use of such labels include U.S. Patent Nos. 3,817,837;
- a fluorescent label is preferred because it provides a very strong signal with low background. It is also optically detectable at high resolution and sensitivity through a quick scanning procedure.
- the nucleic acid samples can all be labeled with a single label, e.g., a single fluorescent label.
- different nucleic acid samples can be simultaneously hybridized where each nucleic acid sample has a different label. For instance, one target could have a green fluorescent label and a second target could have a red fluorescent label. The scanning step will distinguish sites of binding of the red label from those binding the green fluorescent label.
- Each nucleic acid sample (target nucleic acid) can be analyzed independently from one another.
- Suitable chromogens which can be employed include those molecules and compounds which absorb light in a distinctive range of wavelengths so that a color can be observed or, alternatively, which emit light when irradiated with radiation of a particular wave length or wave length range, e.g., fluorescers.
- fluorescent labels should absorb light above about 300 nm, preferably about 350 nm, and more preferably above about 400 nm, usually emitting at wavelengths greater than about 10 nm higher than the wavelength of the light absorbed. It should be noted that the absorption and emission characteristics of the bound dye can differ from the unbound dye. Therefore, when referring to the various wavelength ranges and characteristics of the dyes, it is intended to indicate the dyes as employed and not the dye which is unconjugated and characterized in an arbitrary solvent. 306T-000300PC
- Fluorescers are generally preferred because by irradiating a fluorescer with light, one can obtain a plurality of emissions. Thus, a single label can provide for a plurality of measurable events.
- Detectable signal can also be provided by chemiluminescent and bioluminescent sources.
- Chemiluminescent sources include a compound which becomes electronically excited by a chemical reaction and can then emit light which serves as the detectable signal or donates energy to a fluorescent acceptor.
- luciferins can be used in conjunction with luciferase or lucigenins to provide bioluminescence.
- Spin labels are provided by reporter molecules with an unpaired electron spin which can be detected by electron spin resonance (ESR) spectroscopy.
- exemplary spin labels include organic free radicals, transitional metal complexes, particularly vanadium, copper, iron, and manganese, and the like.
- exemplary spin labels include nitroxide free radicals.
- the label may be added to the target (sample) nucleic acid(s) prior to, or after the hybridization.
- direct labels are detectable labels that are directly attached to or incorporated into the target (sample) nucleic acid prior to hybridization.
- indirect labels are joined to the hybrid duplex after hybridization.
- the indirect label is attached to a binding moiety that has been attached to the target nucleic acid prior to the hybridization.
- the target nucleic acid may be biotinylated before the hybridization. After hybridization, an avidin-conjugated fluorophore will bind the biotin bearing hybrid duplexes providing a label that is easily detected.
- fluorescein labeled UTP and CTP can be incorporated into the RNA produced in an in vitro transcription.
- the labels can be attached directly or through a linker moiety.
- the site of label or linker-label attachment is not limited to any specific position.
- a label may be attached to a nucleoside, nucleotide, or analogue thereof at any position that does not interfere with detection or hybridization as desired.
- Reagents from Clontech provide for labeling interspersed throughout the phosphate backbone of an oligonucleotide and for terminal labeling at the 3' and 5' ends.
- labels can be attached at positions on the ribose ring or the ribose can be modified and even eliminated as desired.
- the base moieties of useful labeling reagents can include those that are naturally occurring or modified in a manner that does not interfere with the purpose to which they are put. Modified bases include but are not limited to 7-deaza A and G, 7-deaza-8-aza A and G, and other heterocyclic moieties.
- fluorescent labels are not to be limited to single species organic molecules, but include inorganic molecules, multi-molecular mixtures of organic and/or inorganic molecules, crystals, heteropolymers, and the like.
- CdSe-CdS core-shell nanocrystals enclosed in a silica shell can be easily derivatized for coupling to a biological molecule (Bruchez et al. (1998) Science, 281: 2013- 2016).
- highly fluorescent quantum dots (zinc sulfide-capped cadmium selenide) have been covalently coupled to biomolecules for use in ultrasensitive biological detection (Warren and Nie (1998) Science, 281: 2016-2018).
- alterations in expression of NELL-1 can be detected and/or quantified by detecting and/or quantifying the amount and/or activity of translated NELL-1 polypeptide.
- the polypeptide(s) encoded by the NELL-1 can be detected and quantified by any of a number of methods well known to those of skill in the art. These may include analytic biochemical methods such as electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, and the like, or various immunological methods such as fluid or gel precipitin reactions, immunodiffusion (single or double), immunoelectrophoresis, radioimmunoassay (RIA), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, western blotting, and the like.
- analytic biochemical methods such as electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, and the like
- various immunological methods such as fluid or gel precipitin reactions, immunodiffusion (single or double), immunoelectroph
- the NELL-1 polypeptide(s) are detected/quantified in an electrophoretic protein separation (e.g. a 1- or 2-dimensional electrophoresis).
- electrophoretic protein separation e.g. a 1- or 2-dimensional electrophoresis.
- Means of detecting proteins using electrophoretic techniques are well known to those of skill in the art (see generally, R. Scopes (1982) Protein Purification, Springer-Nerlag, ⁇ .Y.; Deutscher, (1990) Methods in Enzymology Vol. 182: Guide to
- Western blot (immunoblot) analysis is used to detect and quantify the presence of polypeptide(s) of this invention in the sample.
- This technique generally comprises separating sample proteins by gel electrophoresis on the basis of molecular weight, transferring the separated proteins to a suitable solid support, (such as a nitrocellulose filter, a nylon filter, or derivatized nylon filter), and incubating the sample with the antibodies that specifically bind the target polypeptide(s).
- the antibodies specifically bind to the target polypeptide(s) and may be directly labeled or alternatively may be subsequently detected using labeled antibodies (e.g., labeled sheep anti-mouse antibodies) that specifically bind to the a domain of the antibody.
- labeled antibodies e.g., labeled sheep anti-mouse antibodies
- the NELL-1 polypeptide(s) are detected using an immunoassay.
- an immunoassay is an assay that utilizes an antibody to specifically bind to the analyte (e.g., the target polypeptide(s)). The immunoassay is thus characterized by detection of specific binding of a polypeptide of this invention to an antibody as opposed to the use of other physical or chemical properties to isolate, target, and quantify the analyte.
- Immunological binding assays typically utilize a "capture agent" to specifically bind to and often immobilize the analyte (NELL-1 polypeptide).
- the capture agent is an antibody.
- j-mmunoassays also often utilize a labeling agent to specifically bind to and label the binding complex formed by the capture agent and the analyte.
- the labeling agent may itself be one of the moieties comprising the antibody/analyte complex.
- the labeling agent may be a labeled polypeptide or a labeled antibody that specifically recognizes the already bound target polypeptide.
- the labeling agent may be a third moiety, such as another antibody, that specifically binds to the capture agent
- proteins capable of specifically binding immunoglobulin constant regions such as protein A or protein G may also be used as the label agent. These proteins are normal constituents of the cell walls of streptococcal bacteria. They exhibit a strong non- immunogenic reactivity with immunoglobulin constant regions from a variety of species (see, generally Kronval, et al. (1973) /. Immunol, 111: 1401-1406, and Akerstrom (1985) J. Immunol, 135: 2589-2542).
- Preferred immunoassays for detecting the target polypeptide(s) are either competitive or noncompetitive.
- Noncompetitive immunoassays are assays in which the amount of captured analyte is directly measured.
- the capture agents can be bound directly to a solid substrate where they are immobilized. These immobilized antibodies then capture the target polypeptide present in the test sample. The target polypeptide thus immobilized is then bound by a labeling agent, such as a second antibody bearing a label.
- the amount of analyte (NELL-1 polypeptide) present in the sample is measured indirectly by measuring the amount of an added (exogenous) analyte displaced (or competed away) from a capture agent (antibody) by the analyte present in the sample.
- a known amount of, in this case, labeled polypeptide is added to the sample and the sample is then contacted with a capture agent.
- the amount of labeled polypeptide bound to the antibody is inversely proportional to the concentration of target polypeptide present in the sample.
- the antibody is immobilized on a solid substrate.
- the amount of target polypeptide bound to the antibody may be determined either by measuring the amount of target polypeptide present in an polypeptide /antibody complex, or alternatively by measuring the amount of remaining uncomplexed polypeptide.
- the immunoassay methods of the present invention include an enzyme immunoassay (EIA) which utilizes, depending on the particular protocol employed, unlabeled or labeled (e.g., enzyme-labeled) derivatives of polyclonal or monoclonal antibodies or antibody fragments or single-chain antibodies that bind NELL-1 polypeptide(s), either alone or in combination.
- EIA enzyme immunoassay
- unlabeled or labeled e.g., enzyme-labeled
- a different detectable marker for example, an enzyme-labeled antibody capable of binding to the monoclonal antibody which binds the NELL-1 polypeptide, may be employed.
- EIA enzyme-linked immunoabsorbent assay
- ELISA enzyme-linked immunoabsorbent assay
- immunoblotting immunoassay techniques such as western blotting employing an enzymatic detection system.
- the immunoassay methods of the present invention may also be other known immunoassay methods, for example, fluorescent immunoassays using antibody conjugates or antigen conjugates of fluorescent substances such as fluorescein or rhodamine, latex agglutination with antibody-coated or antigen-coated latex particles, haemagglutination with antibody-coated or antigen-coated red blood corpuscles, and immunoassays employing an avidin-biotin or strepavidin-biotin detection systems, and the like.
- the particular parameters employed in the immunoassays of the present invention can vary widely depending on various factors such as the concentration of antigen in the sample, the nature of the sample, the type of immunoassay employed and the like.
- the amount of antibody that binds NELL- polypeptides is typically selected to give 50% binding of detectable marker in the absence of sample. If purified antibody is used as the antibody source, the amount of antibody used per assay will generally range from about 1 ng to about 100 ng. Typical assay conditions include a temperature range of about 4°C. to about 45°C, preferably about 25°C to about 37°C, and most preferably about 25°C, a pH value range of about 5 to 9, preferably about 7, and an ionic strength varying from that of distilled water to that of about 0.2M sodium chloride, preferably about that of 0.15M sodium chloride.
- Times will vary widely depending upon the nature of the assay, and generally range from about 0.1 minute to about 24 hours.
- buffers for example PBS
- other reagents such as salt to enhance ionic strength, proteins such as serum albumins, stabilizers, biocides and non-ionic detergents may also be included.
- the assays of this invention are scored (as positive or negative or quantity of target polypeptide) according to standard methods well known to those of skill in the art.
- a Western Blot assay can be scored by visualizing the colored product produced by the enzymatic label. A clearly visible colored band or spot at the correct molecular weight is scored as a positive result, while the absence of a clearly visible spot or band is scored as a negative. The intensity of the band or spot can provide a quantitative measure of target polypeptide concentration.
- Antibodies for use in the various immunoassays described herein are commercially available or can be produced as described below.
- Either polyclonal or monoclonal antibodies may be used in the immunoassays of the invention described herein.
- Polyclonal antibodies are preferably raised by multiple injections (e.g. subcutaneous or intramuscular injections) of substantially pure polypeptides or antigenic polypeptides into a suitable non-human mammal.
- the antigenicity of the target peptides can be determined by conventional techniques to determine the magnitude of the antibody response of an animal that has been immunized with the peptide.
- the peptides that are used to raise antibodies for use in the methods of this invention should generally be those which induce production of high titers of antibody with relatively high affinity for target polypeptides encoded by NELL-1.
- the immunizing peptide may be coupled to a carrier protein by conjugation using techniques that are well-known in the art.
- a carrier protein such commonly used carriers which are chemically coupled to the peptide include keyhole limpet hemocyanin (KLH), thyroglobulin, bovine serum albumin (BSA), and tetanus toxoid.
- KLH keyhole limpet hemocyanin
- BSA bovine serum albumin
- tetanus toxoid tetanus toxoid.
- the coupled peptide is then used to immunize the animal (e.g. a mouse or a rabbit).
- the antibodies are then obtained from blood samples taken from the mammal.
- polyclonal antibodies produced by the animals can be further purified, for example, by binding to and elution from a matrix to which the peptide to which the antibodies were raised is bound.
- Those of skill in 306T-000300PC the art will know of various techniques common in the immunology arts for purification and/or concentration of polyclonal antibodies, as well as monoclonal antibodies see, for example, Coligan, et al. (1991) Unit 9, Current Protocols in Immunology, Wiley
- the antibodies produced will be monoclonal antibodies
- mAb's For preparation of monoclonal antibodies, immunization of a mouse or rat is preferred.
- antibody as used in this invention includes intact molecules as well as fragments thereof, such as, Fab and F(ab') , and/or single-chain antibodies (e.g. scFv) which are capable of binding an epitopic determinant.
- scFv single-chain antibodies
- the term “mab's of the invention” refers to monoclonal antibodies with specificity for a polypeptide encoded by a NELL-1 polypeptide.
- hybridomas secreting mAbs The general method used for production of hybridomas secreting mAbs is well known (Kohler and Milstein (1975) Nature, 256:495). Briefly, as described by Kohler and Milstein the technique comprised isolating lymphocytes from regional draining lymph nodes of five separate cancer patients with either melanoma, teratocarcinoma or cancer of the cervix, glioma or lung, (where samples were obtained from surgical specimens), pooling the cells, and fusing the cells with SHFP-1. Hybridomas were screened for production of antibody which bound to cancer cell lines. Confirmation of specificity among mAb's can be accomplished using relatively routine screening techniques (such as the enzyme-linked immunosorbent assay, or "ELISA") to determine the elementary reaction pattern of the mAb of interest.
- ELISA enzyme-linked immunosorbent assay
- Antibodies fragments e.g. single chain antibodies (scFv or others), can also be produced/selected using phage display technology.
- the ability to express antibody fragments on the surface of viruses that infect bacteria (bacteriophage or phage) makes it possible to isolate a single binding antibody fragment, e.g., from a library of greater than 10 10 nonbinding clones.
- phage display an antibody fragment gene is inserted into the gene encoding a phage surface protein (e.g., pUI) and the antibody fragment-pin fusion protein is displayed on the phage surface (McCafferty et al. (1990) Nature, 348: 552-554; Hoogenboom et al. (1991) Nucleic Acids Res. 19: 4133-4137).
- phage bearing antigen binding antibody fragments can be separated from non-binding phage by antigen affinity chromatography (McCafferty et al. (1990) Nature, 348: 552-554).
- Human antibodies can be produced without prior immunization by displaying very large and diverse N-gene repertoires on phage (Marks et al. (1991) J. Mol. Biol. 222: 581-597).
- natural N H and N repertoires present in human peripheral blood lymphocytes are were isolated from unimmunized donors by PCR.
- the N-gene repertoires were spliced together at random using PCR to create a scFv gene repertoire which is was cloned into a phage vector to create a library of 30 million phage antibodies (Id.).
- binding antibody fragments have been isolated against more than 17 different antigens, including haptens, polysaccharides and proteins (Marks et al. (1991) J. Mol. Biol. 222: 581-597; Marks et al. (1993). Bio/Technology. 10: 779-783; Griffiths et al. (1993) EMBO J. 12: 725-734; Clackson et al. (1991) Nature. 352: 624-628). Antibodies have been produced against self proteins, including human thyroglobulin, immunoglobulin, tumor necrosis factor and CEA (Griffiths et al. (1993) EMBO J. 12: 725-734).
- antibodies can be prepared by any of a number of commercial services (e.g., Berkeley antibody laboratories, Bethyl Laboratories, Anawa,
- the assays of this invention have immediate utility in screening for agents that modulate the NELL-1 expression of a cell, tissue or organism.
- the assays of this invention can be optimized for use in particular contexts, depending, for example, on the source and or nature of the biological sample and/or the particular test agents, and/or the analytic facilities available. Thus, for example, optimization can involve determining optimal conditions for binding assays, optimum sample processing conditions (e.g. preferred PCR conditions), hybridization conditions that maximize signal to noise, protocols that improve throughput, etc.
- assay formats can be selected and/or optimized according to the availability of equipment and/or reagents. Thus, for example, where commercial antibodies or ELISA kits are available it may be desired to assay protein concentration. Conversely, where it is desired to screen for modulators that alter transcription the NELL-1 gene, nucleic acid based assays are preferred.
- Pre-screening for agents that bind NELL-1 In certain embodiments it is desired to pre-screen test agents for the ability to interact with (e.g. specifically bind to) a NELL-1 nucleic acid or polypeptide. Specifically binding test agents are more likely to interact with and thereby modulate NELL-1 expression and/or activity. Thus, in some preferred embodiments, the test agent(s) are pre-screened for binding to NELL-1 nucleic acids or to NELL-1 proteins before performing the more complex assays described above.
- such pre-screening is accomplished with simple binding assays.
- Means of assaying for specific binding or the binding affinity of a particular ligand for a nucleic acid or for a protein are well known to those of skill in the art.
- the NELL-1 protein or nucleic acid is immobilized and exposed to a test agent (which can be labeled), or alternatively, the test agent(s) are immobilized and exposed 306T-000300PC to an NELL-1 protein or to a NELL-1 nucleic acid (which can be labeled). The immobilized moiety is then washed to remove any unbound material and the bound test agent or bound
- NELL-1 nucleic acid or protein is detected (e.g. by detection of a label attached to the bound molecule).
- the amount of immobilized label is proportional to the degree of binding between the NELL-1 protein or nucleic acid and the test agent.
- the assays described above provided methods of detecting the presence or absence, or quantifying expression of NELL-1, it will be appreciated that the same assays can be used to screen for agents that modulate the expression of and/or the activity of an MT-SPl serine protease.
- the assays described above are performed in the presence of one or more test agents or are performed using biological samples from cells and/or tissues and/or organs and/or organisms exposed to one or more test agents.
- the MT-SPl activity and/or expression level is determined and, in a preferred embodiment, compared to the activity level(s) observed in "control" assays (e.g., the same assays lacking the test agent).
- a difference between the MT-SPl expression and/or activity in the "test” assay as compared to the control assay indicates that the test agent is a "modulator" of SP1 expression and/or activity.
- the assays of this invention level are deemed to show a positive result, e.g. elevated expression and/or MT-SPl activity, genes, when the measured protein or nucleic acid level or protein activity is greater than the level measured or known for a control sample (e.g. either a level known or measured for a normal healthy cell, tissue or organism mammal of the same species not exposed to the or putative modulator (test agent), or a "baseline/reference" level determined at a different tissue and/or a different time for the same individual).
- the assay is deemed to show a positive result when the difference between sample and "control" is statistically significant (e.g. at the 85% or greater, preferably at the 90% or greater, more preferably at the 95% or greater and most preferably at the 98% or greater confidence level).
- the assays of this invention are also amenable to "high-throughput" modalities.
- new chemical entities with useful properties e.g., modulation of NELL-1 expression or activity
- a chemical compound called a “lead compound”
- HTS high throughput screening
- high throughput screening methods involve providing a library containing a large number of compounds (candidate compounds) potentially having the desired activity.
- Such “combinatorial chemical libraries” are then screened in one or more assays, as described herein, to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity.
- the compounds thus identified can serve as conventional "lead compounds” or can themselves be used as potential or actual therapeutics.
- a combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical "building blocks" such as reagents.
- a linear combinatorial chemical library such as a polypeptide library is formed by combining a set of chemical building blocks called amino acids in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks.
- combinatorial chemical libraries include, but are not limited 306T-000300PC to, peptide libraries (see, e.g., U.S. Patent 5,010,175, Furka (1991) Int. J. Pept. Prot. Res.,
- Peptide synthesis is by no means the only approach envisioned and intended for use with the present invention.
- Other chemistries for generating chemical diversity libraries can also be used. Such chemistries include, but are not limited to: peptoids (PCT Publication No WO 91/19735, 26 Dec. 1991), encoded peptides (PCT Publication WO 93/20242, 14 Oct. 1993), random bio-oligomers
- a number of well known robotic systems have also been developed for solution phase chemistries. These systems include automated workstations like the automated synthesis apparatus developed by Takeda Chemical Industries, LTD. (Osaka, Japan) and many robotic systems utilizing robotic arms (Zymate II, Zymark Corporation, Hopkinton, Mass.; Orca, Hewlett-Packard, Palo Alto, Calif.) which mimic the manual synthetic operations performed by a chemist. Any of the above devices are suitable for use 306T-000300PC with the present invention. The nature and implementation of modifications to these devices
- any of the assays for that modulate expression of NELL-1 or that alter the binding specificity and/or activity of NELL-1 polypeptides are amenable to high throughput screening.
- modulators either inhibit or increase bone mineralization.
- Preferred assays thus detect inhibition of transcription (i.e., inhibition of mRNA production) by the test compound(s), inhibition of protein expression by the test compound(s), or binding to the gene (e.g., gDNA, or cDNA) or gene product (e.g., mRNA or expressed protein) by the test compound(s).
- the assay can detect inhibition of the characteristic activity of the NELL-1 polypeptide.
- high throughput screening systems are commercially available (see, e.g., Zymark Corp., Hopkinton, MA; Air Technical Industries, Mentor, OH; Beckman Instruments, Inc. Fullerton, CA; Precision Systems, Inc., Natick, MA, etc.). These systems typically automate entire procedures including all sample and reagent pipetting, liquid dispensing, timed incubations, and final readings of the microplate in detector(s) appropriate for the assay.
- These configurable systems provide high throughput and rapid start up as well as a high degree of flexibility and customization. The manufacturers of such systems provide detailed protocols the various high throughput.
- Zymark Corp. 306T-000300PC provides technical bulletins describing screening systems for detecting the modulation of gene transcription, ligand binding, and the like.
- this invention provides methods and compositions to enhance bone growth. This is useful in a variety of contexts including, but not limited to, bone reconstruction, such as is used to reconstruct defects occurring as a result of trauma, cancer surgery or errors in development, the treatment of osteogenesis imperfecta, the treatment of osteoporosis, and the healing of major or minor bone fractures.
- the methods generally involve increasing NELL-1 protein concentration at or near a bone or at or in a bone progenitor cell and/or contacting a cell (e.g. a bone progenitor cell) with a NELL-1 polypeptide or with a vector encoding a NELL-1 polypeptide.
- a cell e.g. a bone progenitor cell
- This can be accomplished by transforming a bone precursor cell so that it expresses elevated levels of endogenous NELL-1 or so that it expresses NELL-1 from an exogenous transfected NELL-1 nucleic acid, or by contacting the bone, bone fracture site, bone precursor cells with NELL-1 protein(s) or local or systemic administration of a NELL-1 protein.
- bone progenitor cells refers to any or all of those cells that have the capacity to ultimately form, or contribute to the formation of, new bone tissue. This includes various cells in different stages of differentiation, such as, for example, stem cells, macrophages, fibroblasts, vascular cells, osteoblasts, chondroblasts, osteoclasts, and the like. Bone progenitor cells also include cells that have been isolated and manipulated in vitro, e.g., subjected to stimulation with agents such as cytokines or growth factors or even genetically engineered cells.
- bone progenitor cells that are stimulated using the methods and compositions of the invention are not important, so long as the cells are stimulated in such a way that they are activated and, in the context of in vivo embodiments, ultimately give rise to new bone tissue.
- bone progenitor cell is also used to particularly refer to those cells that are located within, are in contact with, or migrate towards (i.e., "home to"), bone progenitor tissue and which cells directly or indirectly stimulate the formation of mature bone.
- the progenitor cells may be cells that ultimately differentiate into mature bone cells themselves, i.e., cells that "directly" form new bone tissue.
- Bone progenitor cells and bone progenitor tissues may be cells and tissues that, in their natural environment, arrive at an area of active bone growth, repair or regeneration.
- bone progenitor cells may also be cells that are attracted or recruited to such an area. These may be cells that are present within an artificially-created osteotomy site in an animal model.
- Bone progenitor cells may also be isolated from animal or human tissues and maintained in an in vitro environment. Suitable areas of the body from which to obtain bone progenitor cells are areas such as the bone tissue and fluid surrounding a fracture or other skeletal defect (whether or not this is an artificially created site), or indeed, from the bone marrow. Isolated cells may be stimulated using the methods and compositions disclosed herein and, if desired, be returned to an appropriate site in an animal where bone repair is to be stimulated.
- the nucleic-acid containing cells would themselves be a form of therapeutic agent.
- the bone progenitor cells and tissues will be those cells and tissues that arrive at the area of bone fracture or damage that one desires to treat. Accordingly, in treatment embodiments, there is no difficulty associated with the identification of suitable target progenitor cells to which the present therapeutic compositions should be applied. It is sufficient in such cases to obtain an appropriate stimulatory composition (e.g. a NELL-1 polypeptide), as disclosed herein, and contact the site of the bone fracture or defect with the composition. The nature of this biological environment is such that the appropriate cells will become activated in the absence of any further targeting or cellular identification by the practitioner.
- an appropriate stimulatory composition e.g. a NELL-1 polypeptide
- NELL-1 expressing nucleic acids are cloned into gene therapy vectors that are competent to transfect cells (such as human or other mammalian cells) in vitro and/or in vivo.
- Widely used retroviral vectors include those based upon murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLN), Simian Immuno deficiency virus (SIN), human immuno deficiency virus (HTN), and combinations thereof.
- MiLV murine leukemia virus
- GaLN gibbon ape leukemia virus
- SI Simian Immuno deficiency virus
- HTN human immuno deficiency virus
- the vectors are optionally pseudotyped to extend the host range of the vector to cells which are not infected by the retrovirus corresponding to the vector.
- the vesicular stomatitis virus envelope glycoprotein (NSN-G) has been used to construct NSN-G-pseudotyped HIN vectors which can infect hematopoietic stem cells ( ⁇ aldini et al.
- Adeno-associated virus (AAN)-based vectors are also used to transduce cells with target nucleic acids, e.g., in the in vitro production of nucleic acids and peptides, and in in vivo and ex vivo gene therapy procedures. See, West et al. (1987) Virology 160:38-47; 306T-000300PC
- Other suitable viral vectors include herpes virus and vaccinia virus.
- U.S. Patents 5,942,496 and 5,763,416 disclose methods, compositions, kits and devices for use in transferring nucleic acids into bone cells in situ and/or for stimulating bone progenitor cells (see also, Evans and Robbins (1995) J. Bone and Joint Surgery, 11- A(7): 1103-1114, Wolff et al. (1992) /. Cell Sci., 103:1249-1259).
- the ⁇ ELL-1 proteins (or biologically active fragments thereof) of this invention are useful for intravenous, parenteral, topical, oral, or local administration (e.g., by aerosol or transdermally). Particularly preferred modes of administration include intra- arterial injection, injection into fracture sites or delivery in a biodegradable matrix.
- the ⁇ ELL-1 proteins agents are typically combined with a pharmaceutically acceptable carrier (excipient) to form a pharmacological composition.
- Pharmaceutically acceptable carriers can contain a physiologically acceptable compound that acts, for example, to stabilize the composition or to increase or decrease the absorption of the agent.
- Physiologically acceptable compounds can include, for example, carbohydrates, such as glucose, sucrose, or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins, compositions that reduce the clearance or hydrolysis of the anti-mitotic agents, or excipients or other stabilizers and/or buffers.
- physiologically acceptable compounds include wetting agents, emulsifying agents, dispersing agents or preservatives which are particularly useful for preventing the growth or action of microorganisms.
- Various preservatives are well known 306T-000300PC and include, for example, phenol and ascorbic acid.
- a pharmaceutically acceptable carrier including a physiologically acceptable compound depends, for example, on the rout of administration of the anti-mitotic agent and on the particular physio-chemical characteristics of the anti-mitotic agent.
- Preferred formulations for the delivery of bone morphogenic proteins (BMPs) are described in detail in U.S. Patent 5,385,887.
- the pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration.
- unit dosage forms suitable for oral administration include powder, tablets, pills, capsules and lozenges.
- the NELL-1 protein(s) if administered orally, must be protected from digestion. This is typically accomplished either by complexing the protein with a composition to render it resistant to acidic and enzymatic hydrolysis or by packaging the protein in an appropriately resistant carrier such as a liposome.
- Means of protecting compounds from digestion are well known in the art (see, e.g., U.S. Patent 5,391,377 describing lipid compositions for oral delivery of therapeutic agents).
- compositions of this invention are particularly useful for topical administration e.g., in surgical wounds to treat facilitate bone reconstruction and/or repair.
- the compositions are useful for parenteral administration, such as intravenous administration or acliriinistration into a body cavity or lumen of an organ.
- the compositions for administration will commonly comprise a solution of the NELL-1 protein dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier for water-soluble proteins.
- a pharmaceutically acceptable carrier preferably an aqueous carrier for water-soluble proteins.
- a variety of carriers can be used, e.g., buffered saline and the like. These solutions are sterile and generally free of undesirable matter.
- These compositions may be sterilized by conventional, well known sterilization techniques.
- the compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium
- NELL-1 protein in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs.
- the NELL-1 proteins are utilized in the form of a pharmaceutically acceptable 306T-000300PC solution (including reconstitution from a lyophilized form). It is optimal to solubilize the osteogenic protein at concentrations of at least about 1 mg/ml, preferably about 2 to 8 mg/ml, so that a pharmaceutically effective amount of protein can be delivered without undue volumes of carrier being necessary. For some applications, concentrations above 2 mg/ml may be desirable.
- the dosage regimen will be determined by the clinical indication being addressed, as well as by various patient variables (e.g. weight, age, sex) and clinical presentation (e.g. extent of injury, site of injury, etc.).
- the dosage of osteogenic protein will be in the range of from 1 to about 10000 ⁇ g, preferably from about about 10 to 1000 ⁇ g, more preferably from about 10 to 100 j ⁇ g.
- Bone wounds initiate a release of biologically active agents critical to the wound healing process.
- Bone morphogenic proteins which naturally occur in bone, once released from the wound, stimulate osteoinduction and regenerate lost or damaged bone tissue.
- BMP Bone morphogenic proteins
- These same proteins in a purified form, can be used to stimulate bone growth into a biodegradable matrix allowing for artificial creation of bone both within and external to the normal skeletal boundaries.
- NELL-1 proteins can be used to stimulate bone re-mineralization in a manner analogous to the use of bone morphogenic proteins.
- NELL-1 proteins can be administered systemically as discussed above.
- the NELL-1 protein can be applied directly to a bone or bone fracture site. This can be accomplished during surgery (e.g. when setting complex fractures, when reconstructing bone, when performing bone transplants, etc.) or can be accomplished by direct injection.
- sustained delivery vehicles include, but are not limited to biodegradable delivery vehicles.
- Preferred biodegradable delivery vehicles are preferably porous. 306T-000300PC
- Biodegradable materials often separated into two categories: 1) those which are hydrophilic; and 2) those which are hydrophobic.
- Hydrophilic materials demineralized freeze dried bone, ceramic, fibrin, gelatin, etc. possess a high affinity for water which provides for easy incorporation of aqueous NELL-1 protein solutions within the internal porosity of the material.
- Hydrophobic materials L-polylactic acid, D,L- polylactic acid, poly-glycolic acid, etc.), while potentially limitless in their range of porosities, gross size, shape and mechanical characteristics are more difficult to "infiltrate" with aqueous solutions.
- hydrophobic materials are often impregnated with the protein or a surfactant is used to facilitate impregnation with the protein (e.g. NELL-1).
- biodegradable delivery materials comprising materials such as fibrinogen, polylactic acid, porous ceramics, gelatin, agar, and the like, can be found, e.g., in U.S. Patent Nos: 5,736,160, 4,181,983, 4,186,448, 3,902,497, 4,442,655, 4,563,489, 4,596,574, 4,609,551, 4,620,327, and 5,041,138.
- Other delivery vehicles include, but are not limited to bone graft materials.
- Bone graft materials can be derived from natural materials (e.g. transplanted bone or bone fragments), synthetic materials (e.g. various polymers and/or ceramics) or combinations of both. Bone graft materials are typically utilized to fill voids or otherwise replace lost bone material. Such graft materials are also often provided as components of prosthetic devices (e.g., bone replacements or supports) to facilitate tight bonding/annealing of the prosthetic with the living bone.
- prosthetic devices e.g., bone replacements or supports
- Bone grafts using bioactive glasses and calcium phosphates, collagen, mixtures and the like have good biocompatibility and give rise to bone tissue formation and incorporation in some cases.
- a number of different glasses, glass-ceramics, and crystalline phase materials have been used, either alone or in combination with acrylic polymerizable species, and other families of polymers, for restorative purposes.
- Other bone graft materials include a pliable, moldable acrylic-based bone cement reinforced with from 15 to 75% by weight of a bioactive glass together with between 1 and 10% by weight of vitreous mineral fibers (U.S. Pat. No. 4,239,113), bone fillers such as tricalcium phosphate and bioceramic A 2 into bisphenol-A-diglycidyl methacrylate (bis GMA) polymerizable through the action of peroxide systems such as benzoyl peroxide mixed with amines, (Nuillemin et al. (1987) Arch. Otolygol. Head Neck Surg. 113: 836- 840).
- bis GMA bisphenol-A-diglycidyl methacrylate
- graft materials that include bone morphogenic proteins are known.
- U.S. Patent 4,394,370 describes complexes of reconstituted collagen and demineralized bone particles or reconstituted collagen and a solubilized bone morphogenetic protein fabricated in a sponge suitable for in vivo implantation in osseous defects are disclosed.
- U.S. Patent 5,824,084 describes substrates made from a biocompatible, implantable graft material, preferably having a charged surface.
- biocompatible, implantable graft materials include synthetic ceramics comprising calcium phosphate, some polymers, demineralized bone matrix, or mineralized bone matrix. These materials may additionally contain cell adhesion molecules bound to the surface of the substrate.
- cell adhesion molecules refers collectively to laminins, fibronectin, vitronectin, vascular cell adhesion molecules (V-CAM) and intercellular adhesion molecules (I-CAM) and collagen.
- Particularly suitable graft materials include, for example, isolated mineralized cancellous bone sections, powders or granules of mineralized bone, demineralized cancellous bone sections, powders or granules of demineralized bone, guanidine-HCl extracted demineralized bone matrix, sintered cortical or cancellous bone, coralline hydroxyapatite sold by Interpore under the trade name Interpore 500, and granular 306T-000300PC ceramics such as that incorporated into the bone graft substitute Collagraft sold by Zimmer, or filamentous sponges such as those made from collagen by Orquest.
- NELL-1 proteins can be incorporated into any of these graft materials or substituted in place of the bone morphogenic protein.
- kits for practice of the assays or use of the compositions described herein comprise one or more containers containing antibodies and/or nucleic acid probes and/or substrates suitable for detection of NELL-1 expression and/or activity levels.
- the kits may optionally include any reagents and/or apparatus to facilitate practice of the assays described herein.
- reagents include, but are not limited to buffers, labels, labeled antibodies, labeled nucleic acids, filter sets for visualization of fluorescent labels, blotting membranes, and the like.
- kits can comprise a container containing a NELL- 1 protein, or a vector encoding a NELL-1 protein and/or a cell comprising a vector encoding a NELL-1 protein.
- kits may include instructional materials containing directions
- instructional materials typically comprise written or printed materials they are not limited to such. Any medium capable of storing such instructions and communicating them to an end user is contemplated by this invention. Such media include, but are not limited to electronic storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the like. Such media may include addresses to internet sites that provide such instructional materials.
- NELL-1 proteins contain a signal peptide, a ISH 2 -terminal thrombospondin (TSP)-like module
- the human NELL-1 gene expressions were primarily localized in the mesenchymal and osteoblast cells at the osteogenic front, along the parasutural bone margins, and within the condensing mesenchymal cells of newly formed bone.
- a human multiple-organ tissue mRNA blot showed that human NELL-1 was specifically expressed in fetal brain but not in fetal lung, kidney or liver.
- NELL-1 was expressed in rat calvarial osteoprogenitor cells but was largely absent in rat tibia, stromal cell, and fibroblast cell culture.
- Our data suggest that the NELL-1 gene is preferentially expressed in cranial intramembranous bone and neural tissue (neural crest origin).
- Adenoviruses (AD5 with an El-A knock-out and MCV promoter) carrying NELL-1 cDNA were constructed and infected into rat fetal calvarial primary cell cultures and MC3T3 cell lines.
- Viruses were constructed according the following protocol: the 293 cells were co-transfected with 10 mg each of pJM17 (containing defective adenovirus genome) and pAC-CMV-based plasmid (containing sense or antisense rat NELL- 1 using CaPO4) to produce recombinant adenovirus vectors expressing rat NELL-1 in 10-14 days.
- Viruses were plaque-purified and Southern blots were performed to assure the incorporation of the NELL-1 gene.
- Adenoviruses containing the ⁇ -Galactosidase gene were used as a control and examined for the efficacy of infection with different cell types. Approximately 80-90% infection efficiency was observed in both MC3T3 and NTH3T3 cells.
- RNA from cells over- expressing NELL-1 was extracted and mouse cDNA array analysis was performed. Hybridization signals were quantitated by phosphoimager.
- NELL-1 mRNA was faintly expressed from day 14 of gestation with mild increase over the gestation period. Day 14 gestation is the time point when fetal calvaria starts to mineralize. Both primary rat fetal calvarial cell cultures and MC3T3 cell cultures over-expressing NELL-1 showed an increase in mineralization over the ⁇ -Galactosidase control. Over-expression of NELL-1 enhanced mineralization in calvarial osteogenic primary cell cultures by approximately 30 folds on day 17 post-infection compared to the control. These results were based on Von Kossa staining and quantitated by ImagePro software. This relative increase decreased to 2 fold by day 21 post infection.
- Mouse cDNA array results from NELL-1 infected MC3T3 cells showed 20% down regulation in BMP-7 gene expression and a three fold up regulation of the Split Hand and Foot gene compared to the control. These two genes are closed related to bone formation and craniofacial development.
- NELL-1 is closely associated with bone formation and it enhanced mineralization of the calvarial osteoblast-like cells.
- Some of the down stream effectors identified clearly play important roles in bone formation and embryological development.
- Premature cranial suture closure, as seen in CS, may be due to overproduction of cranial bone, and therefore, possibly be associated with the over- expression of the NELL-1 molecule.
- These results and the preliminary protein function analysis results of the NELL-1 classify this protein as a biologically relevant molecule.
- these proteins may act as a modulator, interacting with other growth factors.
- TSP-1 was shown to be a major activator of TGF ⁇ -1 (Francois and Bier (1995) Cell.
- TGF ⁇ -1 is secreted by most cells in an inactive form that is unable to interact with cellular receptors.
- the activity of TGF ⁇ -1 is initially masked by its noncovalent association with a dimer of its NH 2 -terminal propeptide, called latency- associated protein (LAP).
- LAP latency- associated protein
- TSP-1 interacts with the NH 2 -terminal region of LAP, forming a trimolecular complex. Within the complex, a 306T-000300PC conformational change takes place that makes TGF ⁇ -1 accessible to the receptor.
- chordin was revealed to directly bind to ventral BMP-4 (bone morphogenetic proteins 4, one of the TGF ⁇ superfamily) and neutralize the BMP-4 activity (Piccolo et al. (1996) Cell,
- NELL-1 protein may execute their unidentified functions extracellularly by interacting with some of the TGF ⁇ superfamily members. Since
- TGF ⁇ -1 is known as a regulator of osteogenesis
- NELL-1 's effect in enhancing mineralization may be related to its interaction with the TGF ⁇ superfamily.
- Nell-1 was a novel molecule overexpressed during premature cranial suture closure in patients with craniosynostosis (CS), one of the most common congenital craniofacial deformities.
- CS craniosynostosis
- the creation and analysis of transgenic mice overexpressing Nell-1 Nell-1 transgenic animals exhibited CS-like phenotypes that ranged from simple to compound synostoses. Histologically, the osteogenic fronts of abnormally closing/closed sutures in these animals revealed calvarial overgrowth and overlap along with increased osteoblast differentiation and reduced cell proliferation. Furthermore, anomalies were restricted to calvarial bone, despite generalized, non-tissue- specific overexpression of Nell-1.
- Nell-1 overexpression accelerated calvarial osteoblast differentiation and mineralization under normal culture conditions. Moreover, Nell-1 overexpression in osteoblasts was sufficient to promote alkaline phosphatase expression and micronodule formation. Conversely, downregulation of Nell-1 inhibited osteoblast differentiation in vitro.
- Nell-1 overexpression induced calvarial overgrowth resulting in premature suture closure in a rodent model. Nell-1, therefore, has a novel role in CS development, perhaps as part of a complex chain of events resulting in premature suture closure. On a cellular level, Nell-1 expression may modulate and be both sufficient and required for osteoblast differentiation.
- Rat Nell-1 cDNA was subcloned from pTM-70 (13, 14) into pCDNAl.l
- the recombinant plasmid was first tiansfected into MC3T3 cells (a mouse calvarial cell line) to verify proper protein expression (data not shown). The 4.76-kb DNA fragment containing the CMV promoter, Nell-1 cDNA, and the SV40 polyadenylation site was then used for microinjection of oocytes. B6C3 mice were used to generate transgenic mice using standard protocols (15). The founders were mated with their nontransgenic littermates to set up transgenic lines.
- the PCR protocol of establishing transgene copy number was obtained at http://www.med.umich.edu/ tamc/spike.html (16).
- the mass of transgene DNA per 5 Dg genomic DNA was calculated as N bp transgene DNA/3 D 109 genomic DNA, based on the assumption that the haploid content of a mammalian genome is 3 D 109 bp and that it takes 10 Dg DNA to spike.
- the size of the insert is 4.76 kb, and the one-copy standard is 7.933 pg per 10 Dg genomic DNA.
- Thirty cycles of PCR were performed and products were separated on electrophoresis gels with ethidium bromide. The intensities were calculated using Eagle Eye II (Stratagene, La Jolla, California, USA).
- Nell-1 antibody [0177] Detailed preparation of Nell-1 antibody has been documented by Kuroda et al.
- the antibody recognizes the COOH-terminal region of Nell-1 (CSVDLECIENN).
- CSVDLECIENN COOH-terminal region of Nell-1
- the specificity of the antibody was confirmed by Western blot using protein extracted from NeZZ-7-transfected ⁇ IH3T3 cells.
- a standard avidinbiotin complex/immunoperoxidase protocol Vector Elite Kit; Vector Laboratories Inc., Burlingame, California, USA
- Diaminobenzidine peroxidase substrate and 3-amino-9- ethylcarbazole were used for visualization, and sections were counterstained with hematoxylin.
- Magnetic resonance imaging (MRI) was performed on formalin-preserved specimens using a Bruker Biospec MR imager (Bruker BioSpin GmbH, Rheinstetten, Germany) with a 7.0-T, 18-cm clear-bore magnet equipped with a microimaging gradient set and a 35-mm internal diameter birdcage radiofrequency coil.
- Transaxial and sagittal images of the brain and calvarium were obtained using a gradient echo filtered imaging steady-state pulse sequence with the following parameters: TR/TE, 229.3/64.1 ms; flip angle, 30°; field of view, 2.3 cm; matrix, 256 x 256; slice thickness, 1 mm; and number of excitations, 8.
- Inplane spatial resolution was approximately 90 ⁇ m.
- AdNell-1 adenovirus vector harboring Nell-1
- AdAntiNell-1 antisense Nell-1
- Rat Nell-1 cDNA was inserted bidirectionally between the human CMV IEl promoter and the SV40 splice/polyadenylation site flanked by nucleotide sequences from 1 to 454 and from 3,334 to 6,231 of the Ad5 virus.
- the resulting plasmid, pAdCMV-Ne/Z-i transcribes Nell-1 leftward relative to the standard Ad5 map.
- AdNell-1 (AdNell-1) were isolated by cotransfecting 293 cells with pAdCMN-NeZZ-i and pJM17
- Rat calvarial primary cell cultures [0182] The isolation of osteogenic cells from embryonic day 18 (E18) rat calvaria was performed as previously described (12). The cells collected from digestions four, five, and six were pooled and plated at 2.5 x 104/cm2. Cells within passage two were used. Adenoviral infection of osteoblasts. In order to observe the effects of overexpressing Nell-1, osteoblasts from different lineages were grown to 80% confluence in six-well plates. The media was aspirated and an infective dose (20 pfu/cell in 1 ml serum-free medium) was added to the cultures.
- AdNell-1 Five sets of AdNell-1, AdAntiNell-1, and control Ad carrying ⁇ - Galactosidase (Ad ⁇ -Gal) were used. On days 12, 15, and 21 after infection, von Kossa staining was performed. The percentage of area mineralized was analyzed using the Image- Pro Plus system (Media Cybernetics, Silver Spring, Maryland, USA). Comparisons between mice were made using the Student t test. In order to observe the effects of downregulating Nell-1, AdAntiNeZZ-i was added to fetal rat calvarial cell (FRCC) cultures as described above.
- FRCC fetal rat calvarial cell
- Microarrays were performed using R ⁇ A from AdNell-1- and Ad ⁇ -Gal- infected MC3T3 cells at 6, 9, and 12 days after infection. I. Nishimura and the University of California Los Angeles Microarrays Core Facility staff have developed bone-related microarrays. The microarrays contain over 37 genes with more than ten internal control genes.
- Confirmed markers include the following: bone matrix proteins (osteopontin, osteonectin, osteocalcin, bone sialoprotein); receptors ( ⁇ 2-integrin, vitamin D receptor, parathyroid receptor, estrogen receptor); osteoblastic markers (alkaline phosphatase, Cbfal); 306T-000300PC adhesive proteins (fibronectin, chondroitin sulfate proteoglycan 1, decorin, tenascin, syndecan, laminin); metalloproteinases (matrix metalloproteinases 1 and 2); growth factors
- RNA (30 ⁇ g total RNA for Cy3 and 60 ⁇ g for Cy5) was labeled with random hexamer primers and Cy3- or Cy5- dUTP. The reverse transcriptase-labeled probes were hybridized onto the arrays.
- Msx2 forward, 5'-CCT CGG TCA AGT CGG AAA ATT C-3' (SEQ ID ⁇ O:2); reverse, 5'-TGG ACA GGT ACT GTT TCT GGC G- 3' (SEQ ID NO:3); probe, 5'-GAG CAC CGT GGA TAG AGG AG- 3' (SEQ ID NO:4) (annealing temperature, 68°C).
- Cbfal forward, 5'-CTG TGT GGC TCC TAA CAA GTG TG- 3' (SEQ ID NO:5); reverse, 5'-GGA TTC TGG CAA TCA CAA GCT GTC- 3' (SEQ ID NO:6); probe, 5'-CCT ACT CAC TGT CCG GGG AGT CCT GC-3' (SEQ ID NO:7) (annealing temperature, 66°C).
- Osteocalcin forward, 5'-ATG AGG ACC CTC TCT CTG CTC-3' (SEQ ID NO:8); reverse, 5'-GTG GTG CCA TAG ATG CGC TTG-3' (SEQ ID NO:9), probe 5'-CAT GTC AAG CAG GGA GGG CA- 3' (SEQ ID NO: 10), (annealing temperature, 66°C).
- Osteopontin forward, 5'-AGC AGG AAT ACT AAC TGC-3' (SEQ ID NO:ll); reverse, 5'-GAT TAT AGT GAC ACA GAC-3' (SEQ ID NO:12) probe 5'-GCC 306T-000300PC
- Cells were seeded on 60-mm plates at 5 x 105 cells/plate. Cells were harvested at 24, 36, 48, and 72 hours after infection with AdNell-1 and Ad ⁇ -Gal. One million cells were used for flow cytometry, and this procedure was repeated three times. Hypotonic DNA staining buffer containing propidium iodide was added to the cells for flow cytometry.
- mice in which Nell-1 is expressed under the control of the CMV promoter were produced. Copy number was confirmed by Southern blot and PCR ( Figure 2A). R ⁇ A analysis ( Figure 2B) and immunohistochemistry (data not shown) further confirmed expression of ⁇ ell-1 in founders.
- NeZZ-2-overexpressing founders were crossed with nontransgenic littermates, and comprehensive analyses were conducted on F2 progeny. Because most human CS phenotypes are readily apparent in newboms, 42 newborn mice, representing six litters from two lines, were examined. The morphology of these mice was assessed for developmental anomalies, including suture closure. The mice were subsequently genotyped.
- Suture patency was determined by the absence (indicating suture closure) or the presence (indicating suture patency) of visible blood vessels underneath the suture. Suture closure was further confirmed under a dissecting microscope. Two of the six litters examined, representing 20 progeny, did not yield any newboms with obvious craniofacial defects and were Nell-1 transgene negative. These litters were not examined further. Progeny with craniofacial defects were recovered in each of the four remaining litters. The progeny of these four litters (annealing temperature, 66°C).
- Osteocalcin forward, 5'-ATG AGG ACC CTC TCT CTG CTC-3' (SEQ ID NO: 14); reverse, 5'-GTG GTG CCA TAG ATG CGC TTG- 3' (SEQ ID NO: 15), probe 5'-CAT GTC AAG CAG GGA GGG CA- 3' (SEQ ID NO: 16), (annealing temperature, 66°C).
- Osteopontin forward, 5'- AGC AGG AAT ACT AAC TGC-3' (SEQ ID NO: 17); reverse, 5'-GAT TAT AGT GAC ACA GAC-3' (SEQ JD 306T-000300PC
- Nell-1 (12). (22 mice) were analyzed further. A limitation of this rapid screening method is that mild CS with only focal points of suture closure may not be detected, and therefore Nell-1 overexpression might appear to have lower penetrance. [0186] Thirteen (60%) of the 22 newborn progeny were transgenic, with gene copy numbers similar to the founder Nell-1 mice (prediction is 50%). Nell-1 RNA levels of the 13 Nell-1 DNA-positive transgenic F2 (TF2) mice were examined. Eight (62%) were positive for Nell-1 RNA expression. However, the level of expression varied ( Figure 2C).
- RNA levels also differed in different tissues isolated from the same litter. Liu et al. also made this observation of variegation when they overexpressed Msx2 using a CMV promoter (5, 6). Therefore transgenic Nell-1 transcription may not necessarily correlate with gene copy number, and may also vary according to cell type.
- Nell-1 overexpression in our transgenic model was physiologically relevant, we compared Nell-1 RNA expression levels from the whole heads of three TF2 progeny with mild CS phenotypes to levels in nontransgenic normal littermates (NF 2 mice). TF 2 mice displayed up to fourfold- increased Nell-1 expression (data not shown). This was comparable to levels of NELL-1 overexpression in human CS patients in whom two- to fourfold increases have been observed (12). This suggests that Nell-1 overexpression levels in our model were clinically relevant rather than superphysiologic.
- Nell-1 RNA-positive TF 2 mice demonstrated severe craniofacial anomalies and died shortly after birth (see Figures 3A-3C, and Figure 5). These mice also demonstrated detectable Nell-1 transgene expression in their total body mRNA (Figure 2C) that was verified by Nell-1 immunostaining of skin, liver, and calvaria ( Figure 2D).
- Nell-1 expression appears to be confined to the calvaria.
- pan- tissue Nell-1 expression due to the use of the C Vpromoter, TF 2 mice exhibited cranial- specific anomalies that primarily affected calvarial suture patency and closure, hnmunohistochemistry showed increased in vivo expression of osteoblastic differentiation markers ( Figures 4 panels c and d).
- Nell-1 Overexpression of Nell-1 in vitro accelerates osteoblast differentiation.
- Dysregulated bone formation has been proposed as a possible mechanism for calvarial overgrowth/ overlap and premature suture closure (18). Because abnormal suture site osteogenesis is the cardinal feature of Nell-1 TF 2 mice exhibiting premature suture closure, we hypothesized that Nell-1 overexpression may alter normal calvarial osteoblast cell cycling and differentiation pathways to promote premature osteogenesis.
- micronodules late differentiation markers such as osteopontin were not expressed in these "micronodules.”
- AdNeZZ-2-infected osteoblasts in the absence of ascorbic acid suggests that Nell-1 alone may influence cell-cell adhesion but is not sufficient to induce full osteoblast differentiation.
- Microarray analyses used in this experiment were not meant to quantitate the expression of individual genes. Individual gene expression patterns should be interpreted with caution, e.g., genes with two or more fold up or downregulation should then be analyzed. Results should also be confirmed with RT-PCR or R ⁇ A analyses. Late differentiation markers, such as Bmp7, osteopontin, and osteocalcin, were upregulated more than twofold in AdNeZZ-i-infected cells, while earlier markers, such as type I collagen and osteonectin, were downregulated more than twofold (Figure 6G). This suggests that Nell-1 promotes osteoblast differentiation. Osteocalcin and osteopontin R ⁇ A upregulation were verified by R ⁇ A electrophoresis (see Figures 7C and 7D).
- Osteocalcin and osteopontin R ⁇ A expression was also downregulated in AdAntiNeZZ-i cells ( Figures 7C, and 7D).
- the ratio of osteocalcin in AdAntiNeZZ-i-infected cells to osteocalcin in Ad ⁇ Gal controls was less than 1:4 on day 9 and 1 :2 on day 12 by Northern analysis.
- the ratio of osteopontin in AdAntiNeZZ-7-infected cells to that in Ad >-Gal controls was less than 1:5 on days 6 and 9, and less than 2:5 on day 12. Therefore, knockdown data complement the overexpression data and suggest that Nell-1 plays an important role in osteoblast differentiation.
- ⁇ ELL-1 is a relatively newly discovered molecule with previously unknown function. Because of the observed transient upregulation of NELL-1 during premature suture closure in CS patients (12), we simulated NELL-1 overexpression in a mouse model in order to investigate novel potential functions of Nell-1 in craniofacial development and pathology. We observed early suture closure and increased osteoblast differentiation in Nell-1 transgenic mice. Therefore, Nell-1 is likely a candidate for the control of local suture closure, and the overexpression of Nell-1 may play an important role in the mechanism of premature suture closure in CS. Based on our overexpression and knockdown in vitro data, Nell-1 most likely influences osteoblast differentiation. However, the molecular mechanism is unknown.
- ⁇ ell-1 may induce osteoblast differentiation by binding and then sequestering or activating ligands, as well as by triggering receptor-mediated signaling (20).
- ⁇ ell-l's 306T-000300PC combination of chordin-like, cysteine-rich domains, NH 2 -terminal thrombospondin-like module, and EGF-like repeats make it a likely modulator of growth factor activity.
- Nell-1 binds to known EGF-like receptors, we previously added Nell-1 to IL-3-dependent cells expressing ErbBl, -2, -3, or -4. The addition of Nell-1 failed to produce tyrosine phosphorylation of these receptors.
- Nell-1 therefore, is not a ligand for these receptors even though Nell-1 is a known secretory protein with EGF-like repeats (13). Instead, Nell-1 may interact with other specific receptors that may be expressed only by certain cell types.
- yeast two- hybrid system 14
- Nell-1 shares many motifs with thrombospondin-1 and chordin, it may hypothetically activate or sequester members of the TGF- ⁇ superfamily and function as a thrombospondin- 1-like molecule to facilitate latent TGF- ⁇ 1 activation (21). Recently, Abreu et al.
- Nell-1 is a member of the "chordin-like cysteine-rich domains" family, which includes chordin, kielin, crossveinless, twisted gastrulation (Tsg), and connective TGF (20).
- chordin-like cysteine-rich domains family members A common feature of the chordin-like cysteine-rich domains family members is that their expression is temporally and spatially specific, particularly in patterning. Another common feature is their interaction with members of the Bmp family and subsequent function as pro- or anti-Bmp's.
- Nell-1 is preferentially expressed in the craniofacial region, both prenatally and postnatally, during growth and development. Immunohistochemistry showed that Nell-1 localizes primarily to bone-forming areas of sutures and the caivarium and ossifying membranous bone in the mandible (data not shown). Both calvarial and mandibular membranous bones are thought to be neural crest derivatives (22). Preferential Nell-1 expression in the craniofacial region by neural crest derivatives suggests that Nell-1 may be important during skeletal craniofacial growth and development.
- Nell-1 transgenic mice displayed anomalies that were restricted to the calvarial bone, despite generalized, non-tissue-specific Nell-1 overexpression. This further supports our hypothesis that Nell-1 undergoes highly specific interaction to induce osteoblast differentiation. Nell-1 overexpression, therefore, is 306T-000300PC less likely to cause suture closure by nonspecifically perturbing the function of homologous molecules such as thrombospondin-1. This was verified by knockdown studies in vitro.
- RNA microarray analyses of Nell-1 overexpression in osteoblasts cultured under normal conditions demonstrated upregulation of late differentiation markers at day 12 after transfection.
- AdNeZZ-i-transfected osteoblasts also exhibited increased mineralization beginning on day 12 after transfection.
- Nell-1 overexpression may not reflect the true physiological function of ⁇ ell- 1 , but rather the effect of Nell-1 overexpression on other thrombospondin-like molecules. Downregulation of Nell-1 clearly inhibited osteoblast differentiation. ⁇ ell-1 is therefore likely to be both sufficient and required for osteoblast differentiation in vitro. However, Nell- 1 null mice need to be produced in order to justify this conclusion in vivo.
- Nell-1 overexpression produces craniofacial abnormalities similar to those resulting from Msx2 overexpression in vivo. Both mouse models exhibit suture overgrowth and an increased incidence of exencephaly. However, the cellular functions of these two genes appear to be distinctly different; continuous Msx2 overexpression induces proliferation and inhibits differentiation, while Nell-1 enhances differentiation. Mce with a Pro250 ⁇ Arg mutation in Fgfrl, which induces Cbfal overexpression, have distinctly different phenotypes from mice overexpressing Nell-1 because calvarial fusion occurs much later (postnatal days 16-21) and gross suture overlap does not occur (8) in the mice with the Pro250 mutation.
- Cbfal has a similar cellular function to Nell-1 in vitro; both induce osteoblast differentiation with upregulation of bone marker genes.
- Nell-1 expression is modulated by Msx2 and Cbfal.
- Cbfal transfection of FRCCs upregulated Nell-1 expression within 24 306T-000300PC hours, while Msx2 transfection and Cbfal/Msx2 cotransfection downregulated Nell-1 expression (unpublished observations). While all these candidate genes are important to the understanding of CS, Msx2 may be important in the earlier stages of CS (5, 6), while
- Fgfrl/Cbfal may play a role in the later stages of suture closure.
- Future investigation of the Nell-1 promoter, which contains conserved Cbfal and Msx binding sequences, may provide further understanding of their interactions (Figure 8). These observations underscore the complexity of the dynamic genetic and environmental interactions in craniofacial growth and development.
- Nell-1 has not yet been identified as a cause of CS in human genetic studies, the data strongly suggest that Nell-1 is part of a complex chain of events resulting in premature suture closure (1).
- the resemblance of Nell-1 transgenic mice to humans with nonsyndromic CS and Nell- i's association with known CS candidate genes provides new insights for CS research. Further investigation of the regulation and mechanism of Nell-1 in suture closure and bone formation can potentially accelerate our understanding of the cascade of events leading to premature suture closure in CS.
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002498751A CA2498751A1 (en) | 2002-09-13 | 2003-09-15 | Nell-1 enhanced bone mineralization |
EP03752446A EP1551978A4 (en) | 2002-09-13 | 2003-09-15 | Nell-1 enhanced bone mineralization |
AU2003270736A AU2003270736A1 (en) | 2002-09-13 | 2003-09-15 | Nell-1 enhanced bone mineralization |
US10/527,786 US20060111313A1 (en) | 2002-09-13 | 2003-09-15 | Nell-1 enhanced bone mineralization |
JP2004536597A JP2006512292A (en) | 2002-09-13 | 2003-09-15 | Enhancement of bone mineralization by NELL-1 |
DE602004032107T DE602004032107D1 (en) | 2003-02-07 | 2004-02-09 | NELL PEPTIDE EXPRESSION SYSTEMS AND BONE-MAKING NELL PEPTIDE ACTIVITY |
AT04709500T ATE504649T1 (en) | 2003-02-07 | 2004-02-09 | NELL PEPTIDE EXPRESSION SYSTEMS AND BONE FORMING ACTIVITY OF NELL PEPTIDE |
JP2006503442A JP2007524360A (en) | 2003-02-07 | 2004-02-09 | NELL peptide expression system and bone formation activity of NELL peptide |
US10/544,553 US7544486B2 (en) | 2003-02-07 | 2004-02-09 | Nell peptide expression systems and bone formation activity of nell peptide |
EP04709500A EP1594889B1 (en) | 2003-02-07 | 2004-02-09 | Nell peptide expression systems and bone formation activity of nell peptide |
US11/594,510 US7687462B2 (en) | 1999-10-05 | 2006-11-07 | Composition for promoting cartilage formation or repair comprising a nell gene product and method of treating cartilage-related conditions using such composition |
US11/973,831 US20090047275A1 (en) | 2002-09-13 | 2007-10-09 | Nell-1 enhanced bone mineralization |
US11/977,031 US20090060988A1 (en) | 1999-10-05 | 2007-10-22 | Nell-1 enhanced bone mineralization |
US12/700,644 US8044026B2 (en) | 1999-10-05 | 2010-02-04 | Composition for promoting cartilage formation or repair comprising a NELL gene product and method of treating cartilage-related conditions using such composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41084602P | 2002-09-13 | 2002-09-13 | |
US60/410,846 | 2002-09-13 |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/412,297 Continuation US7052856B2 (en) | 1999-10-05 | 1999-10-05 | NELL-1 enhanced bone mineralization |
US10527786 A-371-Of-International | 2003-09-15 | ||
US11/594,510 Continuation-In-Part US7687462B2 (en) | 1999-10-05 | 2006-11-07 | Composition for promoting cartilage formation or repair comprising a nell gene product and method of treating cartilage-related conditions using such composition |
US11/973,831 Continuation US20090047275A1 (en) | 2002-09-13 | 2007-10-09 | Nell-1 enhanced bone mineralization |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004024893A2 true WO2004024893A2 (en) | 2004-03-25 |
WO2004024893A3 WO2004024893A3 (en) | 2004-12-09 |
Family
ID=31994216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/029281 WO2004024893A2 (en) | 1999-10-05 | 2003-09-15 | Nell-1 enhanced bone mineralization |
Country Status (8)
Country | Link |
---|---|
US (2) | US20060111313A1 (en) |
EP (1) | EP1551978A4 (en) |
JP (1) | JP2006512292A (en) |
KR (1) | KR20050084550A (en) |
CN (1) | CN1867673A (en) |
AU (1) | AU2003270736A1 (en) |
CA (1) | CA2498751A1 (en) |
WO (1) | WO2004024893A2 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1851237A2 (en) * | 2005-02-16 | 2007-11-07 | The Regents Of The University Of California | Pharmaceutical compositions for treating or preventing bone conditions |
WO2008060941A2 (en) | 2006-11-17 | 2008-05-22 | The Regents Of The University Of California | Expression system of nell peptide |
US7544486B2 (en) | 2003-02-07 | 2009-06-09 | The Regents Of The University Of California | Nell peptide expression systems and bone formation activity of nell peptide |
EP2089048A2 (en) * | 2006-11-07 | 2009-08-19 | The Regents of the University of California | Composition for cartilage |
WO2010016469A1 (en) | 2008-08-04 | 2010-02-11 | 片山化学工業株式会社 | Technique for regulating regeneration of tissue or faulty or abnormal part in organ using nell-1 |
WO2010042654A2 (en) | 2008-10-07 | 2010-04-15 | The Regents Of The University Of California | Recombinant nell protein production |
US7776361B2 (en) | 1999-10-05 | 2010-08-17 | The Regents Of The University Of California | NELL-1 enhanced bone mineralization |
US7884066B2 (en) | 1999-10-05 | 2011-02-08 | The Regents Of The University Of California | NELL-1 enhanced bone mineralization |
US8877176B2 (en) | 2007-09-28 | 2014-11-04 | Ut-Battelle, Llc | Methods for promoting wound healing and muscle regeneration with the cell signaling protein Nell1 |
US10752663B2 (en) | 2016-08-29 | 2020-08-25 | NellOne Therapeutics, Inc. | Methods and compositions for regenerating tissues |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090060988A1 (en) * | 1999-10-05 | 2009-03-05 | Kang Ting | Nell-1 enhanced bone mineralization |
US20060053503A1 (en) * | 2004-07-30 | 2006-03-09 | Ut-Battelle, Llc | Cranial and vertebral defects associated with loss-of-function of Nell |
WO2009045800A1 (en) * | 2007-09-28 | 2009-04-09 | Culiat Cymbeline T | Treatment of cardiovascular disorders using the cell differentiation signaling protein nell1 |
WO2010062738A1 (en) * | 2008-11-03 | 2010-06-03 | Ut-Battelle, Llc | Diagnosis and treatment of congenital heart defects using nell 1 |
CA2756168A1 (en) | 2009-03-25 | 2010-09-30 | Kang Ting | Isoform nell-1 peptide |
CA2932787A1 (en) * | 2013-12-06 | 2015-06-11 | Novimmune S.A. | Anti-tlr4 antibodies and methods of use thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4394370A (en) * | 1981-09-21 | 1983-07-19 | Jefferies Steven R | Bone graft material for osseous defects and method of making same |
US4409332A (en) * | 1982-01-12 | 1983-10-11 | Jefferies Steven R | Collagen-enzyme conjugates that exhibit no inflammatory response and method for making the same |
US5486359A (en) * | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
US5674844A (en) * | 1991-03-11 | 1997-10-07 | Creative Biomolecules, Inc. | Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
US5674725A (en) * | 1991-07-11 | 1997-10-07 | British Technology Group Limited | Implant materials having a phosphatase and an organophosphorus compound for in vivo mineralization of bone |
US5385887A (en) * | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
US5763416A (en) * | 1994-02-18 | 1998-06-09 | The Regent Of The University Of Michigan | Gene transfer into bone cells and tissues |
US5942496A (en) * | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
US6083690A (en) * | 1995-06-02 | 2000-07-04 | Osteoscreen, Inc. | Methods and compositions for identifying osteogenic agents |
US6352972B1 (en) * | 1995-06-06 | 2002-03-05 | Marcel E. Nimni | Bone morphogenetic proteins and their use in bone growth |
US6008208A (en) * | 1995-10-23 | 1999-12-28 | Osteoscreen, Inc. | Compositions and methods for treating bone deficit conditions |
US6048964A (en) * | 1995-12-12 | 2000-04-11 | Stryker Corporation | Compositions and therapeutic methods using morphogenic proteins and stimulatory factors |
US6200606B1 (en) * | 1996-01-16 | 2001-03-13 | Depuy Orthopaedics, Inc. | Isolation of precursor cells from hematopoietic and nonhematopoietic tissues and their use in vivo bone and cartilage regeneration |
US6005088A (en) * | 1996-03-19 | 1999-12-21 | Otsuka Pharmaceutical Co., Ltd. | Human NPIK gene |
US6077987A (en) * | 1997-09-04 | 2000-06-20 | North Shore-Long Island Jewish Research Institute | Genetic engineering of cells to enhance healing and tissue regeneration |
US6462019B1 (en) * | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
US7052856B2 (en) * | 1999-10-05 | 2006-05-30 | The Regents Of The University Of California | NELL-1 enhanced bone mineralization |
GB0011356D0 (en) * | 2000-05-12 | 2000-06-28 | Univ Nottingham Trent | Medical implant materials |
-
2003
- 2003-09-15 CA CA002498751A patent/CA2498751A1/en not_active Abandoned
- 2003-09-15 WO PCT/US2003/029281 patent/WO2004024893A2/en active Application Filing
- 2003-09-15 US US10/527,786 patent/US20060111313A1/en not_active Abandoned
- 2003-09-15 JP JP2004536597A patent/JP2006512292A/en active Pending
- 2003-09-15 AU AU2003270736A patent/AU2003270736A1/en not_active Abandoned
- 2003-09-15 KR KR1020057004382A patent/KR20050084550A/en not_active Application Discontinuation
- 2003-09-15 CN CNA038249758A patent/CN1867673A/en active Pending
- 2003-09-15 EP EP03752446A patent/EP1551978A4/en not_active Ceased
-
2007
- 2007-10-09 US US11/973,831 patent/US20090047275A1/en not_active Abandoned
Non-Patent Citations (3)
Title |
---|
DATABASE CAPLUS [Online] KIM D. ET AL: 'Nell-1 enhances mineralization in fetal calvarial osteoblastic cells', XP002995459 Retrieved from STN Database accession no. 2000:15500 & SURGICAL FORUM 1999, * |
DATABASE WPI Week 200131, Derwent Publications Ltd., London, GB; AN 2001-300143, XP002903135 TING K: 'Screening for an agent that alters bone mineralization, useful for facilitating bone calcification or repair, comprises contacting a cell containing NELL-1 gene with a test agent and detecting a change in NELL-1 gene expression level' & WO 01 24821 A1 12 April 2001 * |
See also references of EP1551978A2 * |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8044026B2 (en) | 1999-10-05 | 2011-10-25 | The Regents Of The University Of California | Composition for promoting cartilage formation or repair comprising a NELL gene product and method of treating cartilage-related conditions using such composition |
US7884066B2 (en) | 1999-10-05 | 2011-02-08 | The Regents Of The University Of California | NELL-1 enhanced bone mineralization |
US7776361B2 (en) | 1999-10-05 | 2010-08-17 | The Regents Of The University Of California | NELL-1 enhanced bone mineralization |
US8207120B2 (en) | 1999-10-05 | 2012-06-26 | The Regents Of The University Of California | NELL-1 enhanced bone mineralization |
US7687462B2 (en) | 1999-10-05 | 2010-03-30 | The Regents Of The University Of California | Composition for promoting cartilage formation or repair comprising a nell gene product and method of treating cartilage-related conditions using such composition |
US8048646B2 (en) | 2003-02-07 | 2011-11-01 | The Regents Of The University Of California | NELL peptide expression systems and bone formation activity of NELL peptide |
US7807787B2 (en) | 2003-02-07 | 2010-10-05 | The Regents Of The University Of California | NELL-1 peptide |
US7544486B2 (en) | 2003-02-07 | 2009-06-09 | The Regents Of The University Of California | Nell peptide expression systems and bone formation activity of nell peptide |
US7691607B2 (en) | 2004-02-09 | 2010-04-06 | The Regents Of The University Of California | Expression system of NELL peptide |
US8053412B2 (en) | 2004-02-09 | 2011-11-08 | The Regents Of The University Of California | NELL-1 peptides |
US9511115B2 (en) | 2005-02-16 | 2016-12-06 | The Regents Of The University Of California | Pharmaceutical compositions for treating or preventing bone conditions |
EP1851237A4 (en) * | 2005-02-16 | 2009-01-07 | Univ California | Pharmaceutical compositions for treating or preventing bone conditions |
US7833968B2 (en) | 2005-02-16 | 2010-11-16 | The Regents Of The University Of California | Pharmaceutical compositions for treating or preventing bone conditions |
JP2008530227A (en) * | 2005-02-16 | 2008-08-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Pharmaceutical composition for treating or preventing bone conditions |
EP1851237A2 (en) * | 2005-02-16 | 2007-11-07 | The Regents Of The University Of California | Pharmaceutical compositions for treating or preventing bone conditions |
US10335458B2 (en) | 2005-02-16 | 2019-07-02 | The Regents Of The University Of California | Pharmaceutical compositions for treating or preventing bone conditions |
EP2089048A4 (en) * | 2006-11-07 | 2011-02-23 | Univ California | Composition for cartilage |
EP3520804A1 (en) * | 2006-11-07 | 2019-08-07 | The Regents of The University of California | Composition for cartilage |
EP2089048A2 (en) * | 2006-11-07 | 2009-08-19 | The Regents of the University of California | Composition for cartilage |
WO2008060941A2 (en) | 2006-11-17 | 2008-05-22 | The Regents Of The University Of California | Expression system of nell peptide |
US9920104B2 (en) | 2007-09-28 | 2018-03-20 | Ut-Battelle, Llc | Methods for promoting wound healing and muscle regeneration with the cell signaling protein nell1 |
US8877176B2 (en) | 2007-09-28 | 2014-11-04 | Ut-Battelle, Llc | Methods for promoting wound healing and muscle regeneration with the cell signaling protein Nell1 |
WO2010016469A1 (en) | 2008-08-04 | 2010-02-11 | 片山化学工業株式会社 | Technique for regulating regeneration of tissue or faulty or abnormal part in organ using nell-1 |
EP2350286A4 (en) * | 2008-10-07 | 2013-01-09 | Univ California | Recombinant nell protein production |
EP2350286A2 (en) * | 2008-10-07 | 2011-08-03 | The Regents of the University of California | Recombinant nell protein production |
WO2010042654A2 (en) | 2008-10-07 | 2010-04-15 | The Regents Of The University Of California | Recombinant nell protein production |
US10752663B2 (en) | 2016-08-29 | 2020-08-25 | NellOne Therapeutics, Inc. | Methods and compositions for regenerating tissues |
US11034741B2 (en) | 2016-08-29 | 2021-06-15 | NellOne Therapeutics, Inc. | Methods and compositions for regenerating tissues |
US11667684B2 (en) | 2016-08-29 | 2023-06-06 | NellOne Therapeutics, Inc. | Methods and compositions for regenerating tissues |
US11891424B2 (en) | 2016-08-29 | 2024-02-06 | NellOne Therapeutics, Inc. | Methods and compositions for regenerating tissues |
Also Published As
Publication number | Publication date |
---|---|
AU2003270736A1 (en) | 2004-04-30 |
AU2003270736A8 (en) | 2004-04-30 |
CN1867673A (en) | 2006-11-22 |
JP2006512292A (en) | 2006-04-13 |
US20060111313A1 (en) | 2006-05-25 |
EP1551978A4 (en) | 2006-02-01 |
EP1551978A2 (en) | 2005-07-13 |
CA2498751A1 (en) | 2004-03-25 |
WO2004024893A3 (en) | 2004-12-09 |
US20090047275A1 (en) | 2009-02-19 |
KR20050084550A (en) | 2005-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090047275A1 (en) | Nell-1 enhanced bone mineralization | |
US7776361B2 (en) | NELL-1 enhanced bone mineralization | |
Zhang et al. | Craniosynostosis in transgenic mice overexpressing Nell-1 | |
Okamoto et al. | Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development | |
US20030082233A1 (en) | Method and composition for modulating bone growth | |
WO2002043759A2 (en) | Method and composition for modulating bone growth | |
PT1608399E (en) | Complex of sclerostin and noggin or chordin, and agents that modulate the formation of said complex | |
KR20160032077A (en) | Composition for treating or preventing osteoporotic fracture or osteoporosis comprising slit-robo system | |
US20060199781A1 (en) | Assays based on BTF3 activity | |
US20090060988A1 (en) | Nell-1 enhanced bone mineralization | |
US6869766B2 (en) | Gene associated with regulation of adiposity and insulin response | |
JP2002508173A (en) | A method for maintaining or restoring a phenotype appropriate for a tissue of soft tissue cells. | |
US8173613B2 (en) | Modulation of mesenchymal and metastatic cell growth | |
US6673570B1 (en) | Smad associating polypeptides | |
Galaris et al. | Thalgott | |
US20020022026A1 (en) | Genes associated with mechanical stress, expression products therefrom, and uses thereof | |
Clendenning | Determining the role of Growth Differentiation Factor-6 (Gdf6) in the development of the coronal suture | |
Burry | The inter-relation of TGF-Beta, LC3 and apolipoprotein D in the fetal lamb ductus arteriosus | |
Gu | Osteoblastic conversion of non-osteogenic cells: Early responses to osteogenic stimuli | |
Ai | The Consequences of LRP5 Mutations on the Skeleton | |
US20040009511A1 (en) | Identification of compounds which stimulate bone formation using a cell-based screening assay targeting BMP signaling | |
Wang | Function of Atf4 in Endochondral Bone Formation | |
JP2003529746A (en) | Methods for identifying compounds useful for treating bone disease | |
Chalasani | In situ analysis of lymphoid expression of murine semaphorins 4A, 4D, 4F, and 7A | |
WO2001021794A2 (en) | Smad associating polypeptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2498751 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057004382 Country of ref document: KR Ref document number: 2004536597 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003752446 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038249758 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003752446 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057004382 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2006111313 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10527786 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10527786 Country of ref document: US |